

# The Hippo signal transduction network for exercise physiologists

Brendan M. Gabriel<sup>1,7,8</sup>, D Lee Hamilton<sup>2</sup>, Annie M Tremblay<sup>3,4,5</sup>, Henning Wackerhage<sup>1,6\*</sup>

1. School of Medicine, Dentistry and Nutrition, University of Aberdeen, Scotland, UK
2. School of Sport, University of Stirling, Scotland, UK
3. Stem Cell Program, Children's Hospital, Boston, MA, USA
4. Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA
5. Harvard Stem Cell Institute, Cambridge, MA, USA.
6. Faculty of Sport and Health Science, Technical University Munich, Germany
7. The Novo Nordisk Foundation Center for Basic Metabolic Research, Section for Integrative Physiology, University of Copenhagen, Copenhagen, Denmark
8. Integrative physiology, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden

BMG, DLH, AMT and HW all contributed to the conception and writing of this review.

Running head: The Hippo pathway for exercise physiologists

\*Corresponding author:

Prof Henning Wackerhage  
Faculty for Sport and Health Sciences  
Technical University Munich  
Uptown München-Campus D  
Georg-Brauchle-Ring 60/62  
D-80992 München  
Germany  
Email: henning.wackerhage@tum.de  
Tel: +49.89.289.24601  
Fax: +49.89.289.24605

35     **Abstract**

36     The ubiquitous transcriptional co-activators Yap (gene symbol *Yap1*) and Taz (gene symbol  
37     *Wwtr1*) regulate gene expression mainly by co-activating the Tead transcription factors.  
38     Being at the centre of the Hippo signalling network, Yap and Taz are regulated by the Hippo  
39     kinase cassette and additionally by a plethora of often exercise-associated signals and  
40     signalling modules. These include mechanotransduction, the AKT-mTORC1 network, the  
41     SMAD transcription factors, hypoxia, glucose homeostasis, AMPK, adrenaline/epinephrine  
42     and angiotensin II through G protein-coupled receptors, and interleukin 6 (Il-6).  
43     Consequently, exercise should alter Hippo signalling in several organs to mediate at least  
44     some aspects of the organ-specific adaptations to exercise. Indeed, Tead1 overexpression  
45     in muscle fibres has been shown to promote a fast-to-slow fibre type switch, whereas Yap in  
46     muscle fibres and cardiomyocytes promotes skeletal muscle hypertrophy and cardiomyocyte  
47     adaptations, respectively. Finally, genome wide-association studies in humans have linked  
48     the Hippo pathway members *LATS2*, *TEAD1*, *YAP1*, *VGLL2*, *VGLL3* and *VGLL4* to body  
49     height, which is a key factor in sports.

50

51

52     **Keywords**

53     Exercise, Hippo, Hypertrophy, Skeletal Muscle, Yap

54

## 55     **Introduction**

56     Especially during the last decade, key discoveries have led to the characterisation of the  
57     mammalian Hippo signal transduction pathway or network (51, 141, 159). The Hippo signal  
58     transduction network is relevant for exercise physiologists because many exercise-  
59     associated signals and signalling molecules affect Hippo signalling. Additionally, Hippo  
60     effectors regulate several exercise-related genes and adaptations. Starting with Booth in the  
61     mid-1990s (19), exercise physiologists have sporadically studied the Hippo pathway  
62     members in an exercise context. However, to date only few studies on Hippo in an exercise  
63     context have been published. In this review, we will first introduce the Hippo pathway to  
64     exercise physiologists. We will then discuss evidence showing that exercise-associated  
65     signals and signalling modules cross-talk to the key Hippo effectors YAP and TAZ. Next, we  
66     will review studies that implicate Hippo signalling in the regulation of exercise adaptations.  
67     Finally, we will discuss the emerging genetic link between Hippo and body height, a key  
68     variable linked to performance in several sports.

69

## 70     **Hippo signal transduction pathway and network**

71     The discovery of the Hippo pathway is based on two strands of research. First, since the  
72     early 20<sup>th</sup> century, researchers have used the fruit fly (*Drosophila melanogaster*) to identify  
73     genes whose knock out results in cancer-like overgrowth (40). Since 1995, this line of  
74     research has led to the discovery of the several growth-inhibiting genes (68, 156) that  
75     together form the core Hippo pathway (56). In the fly, the mutation of one kinase resulted in  
76     an overgrown head that reminded the researchers of the Hippopotamus' skin. Consequently,  
77     this kinase was named *hippo* by the Halder group. (134). Subsequently "Hippo" was adopted  
78     as the name for the pathway in both the fly and mammals. The Hippo pathway is highly  
79     conserved evolutionarily (60). In mammals (see Figure 1 for a schematic of the mammalian  
80     Hippo pathway), two homologues of the fly *hippo* gene exist, namely the upstream kinases  
81     Mst1 (*Stk4*) and Mst2 (*Stk3*). With the help of scaffolding proteins, Mst1 and Mst2 activate  
82     the downstream kinases Lats1 and Lats2. Recently, Map4k4/6/7 isoforms were identified as

83 alternative kinases capable of phosphorylating Lats1/2 (82, 97, 165). Phosphorylated Lats1  
84 and Lats2 then inhibit the transcriptional co-factors Yap and Taz by phosphorylating multiple  
85 serine residues (86, 162).

86

87 The second strand of research started with the identification of CATTCC DNA motifs, termed  
88 muscle CAT (MCAT) (90) or GTIIC (24) motifs. Such CATTCC DNA motifs and their reverse  
89 strand GGAATG complement form a DNA binding site for the Tead (TEA domain)  
90 transcription factors (named Transcription enhancer factors or Tefs in earlier papers) (6, 24).  
91 Teads repress their target genes, especially when bound by their co-repressor Vgll4 (66,  
92 76). Teads only become activated when bound by the transcriptional co-factor Yap (Yes1-  
93 associated protein; gene symbol *Yap1*), which was discovered by Sudol (122, 123, 138). In  
94 contrast to the fly, mammals possess a Yap paralogue termed Taz (Transcriptional  
95 coactivator with PDZ-binding motif (70)).


96

97 The two origins of Hippo research were only merged when the Pan group demonstrated that  
98 the Hippo kinase cascade inhibited Yorkie, the fly homologue of Yap and Taz (63). Hippo  
99 research then developed exponentially especially after the Pan group (29) and Camargo  
100 from the Jaenisch group (18) both found that the expression of a constitutively active *YAP1*  
101 *S127A* in mouse livers resulted in a 4-fold liver size increase. These landmark findings  
102 confirmed that Yap also functions as a highly potent organ size regulator in mammals.

103

104 However, the Hippo kinase (i.e. the Mst1/2-Lats1/2 kinase cascade) is only one of many  
105 signalling modules that regulate the activity of Yap and Taz. For this reason, it seems most  
106 appropriate to refer to the wider signalling system as the Hippo signal transduction network.  
107 Importantly, numerous exercise-related signals also cross-talk to Yap and Taz, as illustrated  
108 in **Figure 1** and discussed in the next section.

109



**Figure 1.** Schematic representation of the Hippo signal transduction network and its links to exercise-associated signals and signalling modules. **A**, MST1, MST2, LATS1 and LATS2 form the core kinase cassette of the Hippo pathway. SAV1 and MOB1 act as scaffolding proteins. The MAP4K 4, 6 and 7 kinase isoforms can independently regulate LATS1/2 (82, 97, 165). Active LATS1 and LATS2 inhibits YAP and TAZ through the phosphorylation of multiple HXRXXS motifs (where “S” indicates the phosphorylated serine) (162). Phosphorylation of YAP on serine 127 generates a binding site for 14-3-3 proteins, which sequester YAP and TAZ in the cytoplasm. Phosphorylation of serine 381 results in the ubiquitination and degradation of YAP (162). Similar regulatory events also affect TAZ. **B**, The

classical model stipulates that active unphosphorylated YAP and TAZ are nuclear and co-activate the TEAD transcription factors, whereas VGLL4 acts as a repressor. YAP/TAZ-TEAD complexes bind the CATTCC/GGAATG (MCAT or GTIIC) motifs found especially in enhancers that loop to the promoters of genes even though they are located several base pairs away from the promoter itself (39). **C**, Resistance (strength) exercise and muscle growth-associated signals that are linked to YAP/TAZ (see text for more detail). **D**, Endurance exercise-associated signals that are linked to YAP/TAZ (see text for more detail).

110

## 111 **Cross-talk between exercise-related signalling molecules and Hippo**

### 112 **Mechanotransduction**

113 Mechanical loading, in the form of resistance exercise or synergist ablation, stimulates  
114 skeletal muscle growth (42). However, the molecular mechanosensor that triggers growth  
115 processes in response to mechanical loading has long remained elusive. Additionally, the  
116 stiffness of the cellular environment or niche is an additional mechanical signal that  
117 influences for example the differentiation of mesenchymal stem cells into muscle and other  
118 cell types (34, 35). Moreover, mechanical cues also influence the fate of resident stem cells  
119 in skeletal muscle, named satellite cells (41). To identify signalling molecules that regulate  
120 gene expression in response to the mechanical signal triggered by substrate stiffness, the  
121 Piccolo group cultured mammary epithelial cells (MEC) on soft and stiff substrates. They  
122 found that Hippo-related genes showed the most important changes between the two  
123 conditions in terms of expression levels (31). Subsequent experiments confirmed that stiffer  
124 substrates led to increased Yap/Taz activity in a cytoskeleton-dependent manner (31). Later,  
125 it was shown that increased cell-cell contact reduces the mechanical loading of cells, which  
126 explained the previously observed (163) deactivation of Yap and Taz in response to cell-cell  
127 contact at high cell density (8). Whilst this is intriguing and relevant for processes such as  
128 myoblast differentiation, it is unclear whether mechanical changes of the extracellular matrix  
129 during exercise regulate transcriptional responses through Yap and Taz in muscle fibres or  
130 satellite cells.

131

132 In skeletal muscle, the Höhfeld group has identified a specific Hippo and autophagy-  
133 regulating mechanosensor complex located at the Z disc. In this complex, the protein Bag3  
134 senses mechanical unfolding of the actin-crosslinking protein filamin (135). Importantly,  
135 Bag3 contains a WW domain, a rare protein domain frequently found in Hippo members  
136 (WW indicates two tryptophan residues; reviewed by (124)). The location of Bag3 in the Z  
137 disc is an ideal position for a mechanosensor. Indeed, unlike proteins that lie in parallel to  
138 the force-generating sarcomeres, such as integrins, Z disc proteins directly experience  
139 contractile force. One Hippo-independent function of Bag3 is to mediate tension-induced  
140 autophagy, which might contribute to the increased protein breakdown observed during  
141 resistance exercise (127). Additionally, Bag3 regulates Yap and Taz activity by binding to  
142 Yap and Taz binding partners, such as the Hippo kinase Lats1, Amotl1 and Amotl2  
143 (reviewed in (102)). Given that increased Yap activity can promote muscle hypertrophy (46,  
144 148), Bag3-Hippo mechanosensing might be one of the several mechanisms regulating  
145 muscle growth in response to mechanical signals. The importance of Bag3 for skeletal  
146 muscle is further demonstrated by the finding that a loss-of-function of Bag3 causes severe  
147 myopathy symptoms in mice and humans (62, 117). Moreover, the phosphorylation of  
148 human BAG3 on Thr285 and Ser 289 decreases in response to endurance exercise (61).  
149 Also, BAG3 expression decreases after acute high intensity resistance exercise, but  
150 increases together with force-bearing cytoskeleton proteins (136). Therefore, the Hippo-  
151 dependent and -independent functions of Bag3 are of potentially great interest to exercise  
152 physiologists. Currently, it is unclear whether Bag3 is the major mediator of mechanical  
153 loading-induced hypertrophy or whether it mainly senses the changes in the stiffness of a  
154 cell's niche, for example satellite cells, and accordingly regulates their behaviour (34).

155

#### 156 **Cross-talk with Akt-Tsc-mTOR signalling**

157 The mTOR pathway has first been linked to overload-induced muscle growth by Baar and  
158 Esser. They demonstrated that the phosphorylation of the mTOR-related kinase p70 S6k

correlated with increased muscle mass in a rat electrical muscle stimulation model (11). Since then, many studies have confirmed the key role of mTOR signalling for resistance exercise-induced muscle hypertrophy. This includes a study in humans showing that the mTORC1 inhibitor rapamycin prevented the increased muscle protein synthesis triggered by resistance exercise (28).

Given that both the Hippo and mTOR networks regulate organ size, it is intuitive to assume a cross-talk between the mTOR and Hippo signalling pathways. This is indeed the case. Akt was initially shown to phosphorylate Yap on Ser127 (13) but this finding was not confirmed by subsequent studies. In another study, the Hippo kinase Mst1 (gene symbol *Stk4*) was shown to bind and inhibit Akt1 (also known as Pkb) (22). Conversely, Akt phosphorylates Mst1 on Thr387 (65) and Thr120 (161), suggesting that Akt1 and Mst1 regulate each other's activity. Additionally, the Hippo effector Yap de-represses mTOR by inhibiting the expression of the phosphatase Pten via the Pten-targeting miRNA miR-29 (133). Cross-talk also exists between Tsc1 and Tsc2 and the Hippo effector Yap as Tsc1/2-deficient cells have higher Yap levels due to less Yap degradation via the autophagosome system (83). YAP/TAZ also increase the expression of genes that encode the leucine transporter LAT1 (52), which is significant because leucine is a potent stimulator of mTORC1 signalling (10). Collectively, these findings demonstrate that Hippo and mTOR-mediated growth signals are closely coupled by multiple mechanisms. However, a caveat of this research from an exercise physiology standpoint is that most of the above studies have been conducted in cancer models. Therefore, molecular exercise physiologists now need to test whether these mechanisms also function in an exercise context.

### **Cross-talk with myostatin-Smad signalling**

TGF $\beta$  and BMPs are two classes of small extracellular molecules that bind to activin receptors. Bound activin receptors then either phosphorylate the receptor-regulated Smad2/3 or Smad1/5/8 proteins, respectively. These two classes of receptor-regulated



Smads compete for the common mediator Smad4 to form either transcriptionally active Smad2/3-4 complexes promoting muscle loss or Smad1/3/5-4 complexes that have recently been proposed to promote muscle growth (114). In skeletal muscle, the knockout of myostatin (gene symbol *Gdf8*, a TGF $\beta$ -related ligand) or its “natural” loss-of-function mutation resulted in a doubling of the muscle size in mice and cattle, respectively (48, 69, 95, 96). The link between myostatin and muscle mass was confirmed in humans by showing that a toddler with a high muscle mass was homozygous for a knockout mutation in the first intron of the human myostatin-encoding *GDF8* gene (116). Furthermore, dogs with a heterozygous loss of *Gdf8* show increased racing performance (105), linking myostatin not only to muscle mass but also to actual athletic performance. If the loss of myostatin is combined with the overexpression of a follistatin transgene, then muscle mass quadruples, suggesting that myostatin is not the only muscle mass regulator in the TGF $\beta$ -Smad system (79).

Several studies have shown that Yap and Taz co-regulate not only Teads but also several other transcription factors, including Smads (143). In line with this, the overexpression of Yap in mouse tibialis anterior muscle reduced the activity of a Smad binding element (SBE) reporter by approximately 85% (46). In contrast, the overexpression of Yap in myoblasts, which are activated satellite cells, potently increases the expression of the Smad regulator Bmp4 (67). This is intriguing because both Yap (67) and Bmp4 (109) stimulate satellite cell proliferation while inhibiting differentiation into myotubes. Several mechanisms have been proposed that can explain how Yap or Taz can interact with Smads. These include the binding of Yap to the inhibitory Smad7 (7, 49), the promotion of Smad1 transcriptional action by Yap binding (3), and an effect of Yap and Taz on Smad2/3 localisation (137). For molecular exercise physiologists, the challenge is to determine whether Hippo-Smad cross-talk regulates exercise phenomena and especially where it is involved in skeletal muscle mass regulation.

## **Cross-talk with AMPK and glucose signalling**

In the above sections, we have discussed the mechanisms connecting the Hippo network to resistance exercise and organ growth signals and signalling modules. Below, we will discuss the cross-talk between Hippo signalling and endurance exercise.

During the transition from rest to exercise ATP turnover can rise potentially more than 200 fold (98). To maintain homeostasis during such a large step change in ATP hydrolysis, systems have evolved to sense energy levels and initiate the signalling processes regulating both short- and long-term adaptations of energy metabolism. In this system, glucose, glycogen, AMP and ADP are sensed principally by the heterotrimeric AMPK complex (53, 55). Indeed, exercise increases the concentrations of AMP and ADP in contracting skeletal and cardiac muscle and exercise depletes glycogen, especially in muscle (45). Therefore, it comes as no surprise that AMPK is a key mediator of the adaptation to endurance exercise, particularly in skeletal muscle (54). Several recent studies have demonstrated that AMPK is a regulator of YAP, linking a key exercise kinase to Hippo signalling.

Both glucose starvation (36, 100, 145) and AMPK activators (26, 100, 145) inhibit Yap in different cell types. This suggests that Yap-dependent growth is inhibited when cellular energy levels are low. Further work led to the identification of the molecular mechanisms mediating this effect. These include the phosphorylation of the Yap regulator Amotl1 on Ser293 by AMPK (26) and the direct phosphorylation of YAP on Ser61/94, which is key for the interaction between Yap and Teads (100, 145). In another study, the Dupont group showed that the glycolytic enzyme phosphofructokinase (*PFK1*) directly binds to and regulates YAP and TAZ (36). Finally, two studies have identified the AMPK-kinase LKB1 (gene symbol *STK11*) as an AMPK-independent YAP regulator (101, 108). Collectively, these studies demonstrate that glucose starvation and energy stress inhibit YAP via both AMPK-dependent and -independent mechanisms in multiple cell types.

The fact that energy stress and the key exercise kinase AMPK regulate Yap suggest that Yap should be affected by exercise and diet. This now needs to be demonstrated in an exercise model. Also, because Hippo signalling responds to glucose and regulates the expression of glucose transporters (145), it should be studied whether Hippo signalling mediates the augmented adaptations in response endurance training under low carbohydrate supply (12), or mediates some of the anti-diabetic effects of exercise.

### **Cross-talk with hypoxia signalling**

During evolution, the rise in atmospheric oxygen was followed by the evolution of oxidative phosphorylation by mitochondria, which use oxygen as their main electron acceptor. The emergence of oxygen-related metabolism drove the evolution of oxygen-sensing systems, as oxygen became critical for survival. Oxygen-sensing systems allow cells and organisms to adapt to low oxygen levels (i.e., hypoxia) especially through the transcription factor hypoxia-inducible factor (Hif1). Hypoxic conditions lead to an increase in the expression levels of the Hif1 $\alpha$  isoform by blocking its degradation. The hypoxia-induced increase of Hif1 $\alpha$  then induces multiple adaptations through gene expression (126). During exercise, hypoxia-induced signalling is also at work. For example, HIF1 $\alpha$  levels increase in response to normoxic endurance exercise (5). Moreover, altitude training is often used to stimulate the molecular adaptations to hypoxia, including the EPO-mediated haematopoiesis that increases the athlete's oxygen transport capacity (118).

Hypoxia and Hippo signalling also interact. For example, hypoxia activates the E3 ligase Siah2, which leads to the degradation of Lats2. This results in a decreased level of Yap phosphorylation, increasing the activity of Yap in the nucleus (88). Additionally, Yap directly interacts with and stabilises Hif1 $\alpha$  (88). Hif1 $\alpha$  also promotes the expression of Taz and Taz transactivates Hif1 $\alpha$ , highlighting a mechanism by which Taz and Hif1 $\alpha$  are acting as reciprocal co-activators (153). It is unknown whether hypoxia-Hippo mechanisms function

during normoxic endurance exercise (5) and mediate adaptations to high altitude or low-intensity occlusion training. Direct evidence in an exercise or altitude model is required.

### **Sensing of catecholamines and other G protein-coupled receptors (GPCRs) ligands by Hippo**

Catecholamines, such as adrenaline (US: epinephrine) and noradrenaline (US: norepinephrine), mediate the “fight-or-flight” responses. Catecholamine concentrations generally increase with the intensity and duration of exercise and drive the systemic responses to exercise via the  $\alpha$ - and  $\beta$ -adrenergic receptors. These receptors, in turn, signal through G-protein coupled receptors (GPCRs) to trigger exercise adaptations, such as increasing the heart rate and muscle contractility. Moreover,  $\beta$ 2 agonists such as clenbuterol promote skeletal muscle hypertrophy, suggesting an involvement of this system in the control of skeletal muscle growth (89). In the renin-angiotensin system (RAS), the angiotensin receptors are also coupled to protein G. The RAS was related to exercise when the ACE I/D polymorphism was associated with exercise-related traits, such as strength and endurance (111). Also, angiotensin II contributes to the adaptation to overload-induced skeletal muscle hypertrophy (47) and stretch-induced cardiac hypertrophy (112). In accordance with this, the ACE I/D polymorphism was associated with the left ventricular mass changes occurring in response to endurance training (103).

Multiple studies have linked GPCRs to Hippo signalling. Adrenaline/epinephrine represses YAP/TAZ through  $G_{\alpha_s}$ -coupled GPCRs and protein kinase A (PKA) (74, 158). In contrast, angiotensin II and other ligands signal through the  $G_{\alpha_{12/13}}$  and  $G_{\alpha_{q/11}}$  GPCRs to activate YAP/TAZ (150, 160). Given that Yap has been shown to mediate skeletal muscle hypertrophy (46, 148) and can promote cardiac hypertrophy (reviewed in (141)), it will be key to test whether GPCR-Hippo signalling is involved in mediating such adaptations.

## Interleukin-6 and Hippo

Interleukin-6 is a myokine (i.e. a circulating signalling molecule) that is produced by contracting muscle but whose functions are incompletely understood (106, 110). Recently, interleukin-6 has been shown to activate Yap through the gp130 co-receptor in the intestine (125). However, it remains unclear whether this mechanism explains some of the effects of exercise-generated interleukin-6.

## Hippo & exercise-related phenomena

In the text above we have shown that many resistance and endurance exercise-associated signals can cross-talk to the Hippo signal transduction network (see **Figure 1**). However, much of this evidence was obtained in the context of cancer or non-exercise contexts. In the following section, we will review a small number of studies that provide evidence for a role of Hippo signalling in the adaptation to exercise. In relation to this, some key findings are summarised in **Table 1**. Additionally, we review emerging evidence that body height is associated with single nucleotide polymorphisms (SNPs) in the vicinity of Hippo genes.

**Table 1** Key experiments where the perturbation of Hippo members affects skeletal and cardiac muscle in a way that is relevant to exercise physiology.

Key protein, experiment	Effects of intervention versus control	Reference
<b>MST1:</b> <i>STK4</i> (protein MST1) knockout versus wildtype mice, denervation-induced atrophy <i>in vivo</i>	<b>Attenuation of atrophy:</b> skeletal muscle atrophy after denervation ↓; expression of atrophy mediators ↓.	(149)
<b>YAP:</b> Injection of rAAV vector to express the main <i>YAP1</i> isoform versus control into mouse tibialis anterior <i>in vivo</i>	<b>Hypertrophy:</b> Skeletal muscle mass per body weight ↑; fibre cross sectional area ↑; protein synthesis ↑ (no evidence for mTOR involvement).	(148)
<b>YAP:</b> Electroporation of <i>YAP1</i>	<b>Hypertrophy:</b> Fibre cross sectional	(46)

versus control constructs into mouse tibialis anterior <i>in vivo</i>	area ↑ (mTORC1 independent); MyoD reporter ↑; c-Myc reporter ↑, MurRF1 reporter ↓; Smad reporter ↓.	
<b>YAP:</b> Overexpression of <i>YAP1</i> S127A, wildtype <i>YAP</i> or empty vector in satellite cells or cultured muscle fibres <i>in vitro</i>	<b>Satellite cell proliferation</b> ↑; differentiation ↓.	(67)
<b>TAZ:</b> Injection of TAZ activator IBS008738 (specificity unclear) versus vehicle into mouse tibialis anterior after cardiotoxin-induced injury or dexamethasone-induced atrophy <i>in vivo</i>	<b>Regeneration, atrophy prevention:</b> IBS008738 injections accelerated skeletal muscle regeneration after injury and reduced atrophy after dexamethasone-induced atrophy.	(157)
<b>TEAD1:</b> Muscle creatine kinase promoter-driven expression of <i>TEAD1</i> in mouse muscle fibres and heart <i>in vivo</i>	<b>Fast-to-slow muscle phenotype shift but cardiomyopathy:</b> Extensor digitorum longus shortening velocity ↓; peak power ↓ by ~40%; fast-to-slow shift in myosin heavy chains; cardiomyopathy and heart failure.	(130, 132)
<b>YAP:</b> Transduction of neonatal rat cardiomyocytes with Yap1 or control adenovirus <i>in vitro</i>	<b>Cardiomyocyte hypertrophy:</b> Cardiomyocyte size ↑ (Akt-independent) and survival ↑ (Akt-dependent).	(25)
<b>YAP:</b> Inducible, Tnnt2-promoter driven expression of <i>YAP1</i> S127A in foetal and post-natal cardiomyocytes <i>in vivo</i>	<b>Cardiac proliferation:</b> Cardiomyocyte proliferation ↑; relative heart weight ↑; regulation of cell cycle-related genes.	(139)
<b>Salvador:</b> Inducible, Myh6-driven	<b>Cardiac proliferation,</b>	(58)

knock out of *Wwtr1* (Salvador), *Lats1* and *Lats2* in adult cardiomyocytes in mice *in vivo*; apex resection or myocardial infarction

**regeneration:** cardiomyocyte proliferation ↑, regeneration of injured hearts.

**YAP:** α myosin heavy chain-driven expression of *Yap1 S112A* in the mouse heart *in vivo* (homologue of human S127A mutation); myocardial infarction

**Cardiac proliferation,**  
**regeneration:** Cardiomyocyte proliferation ↑; relative heart weight ↑. After myocardial infarction: cardiac function ↑, cardiomyocyte proliferation ↑, fibrosis ↓.

(154)

**YAP:** inducible expression of α myosin heavy chain-driven expression of *Yap1 S127A* in the adult mouse heart *in vivo*; myocardial infarction

**Cardiac proliferation,**  
**regeneration:** Cardiomyocyte proliferation ↑; relative heart weight unchanged. After myocardial infarction: cardiac function ↑, cardiomyocyte proliferation ↑, scar size ↓.

(85)

315 rAAV, recombinant adeno-associated virus; Nkx2.5 and Tnnt2 are promoters used to drive  
316 the specific expression of genes in cardiomyocytes.

317

### 318 **Hippo and adaptive changes in skeletal muscle fibre phenotypes**

319 Gollnick and Saltin were the first to demonstrate a higher percentage of slow type 1 muscle  
320 fibres and a higher oxidative activity in the muscles of endurance athletes when compared to  
321 controls and other athletes (44). They also observed a non-significant increase from 32% to  
322 36% in the frequency of slow type 1 fibres in response to endurance training (43).  
323 Subsequent research has shown that chronic exercise training programmes mainly induce  
324 type 2X-to-2A interconversions (151).

325

In the early 2000's, the Tsika group investigated the role of MCAT elements and Tead1 transcription factors in the regulation of muscle fibre type-specific gene expression (71, 131, 140). The functional relevance of this work was demonstrated *in vivo* using a creatine kinase muscle (CKM) promoter to overexpress Tead1 in mouse skeletal muscle fibres, which caused an increased in slow muscle-specific gene expression *in vivo* (Table 1, (132)). Functionally, CKM-driven Tead1 overexpression reduced the shortening velocity ( $V_{max}$ ) and increased the contraction and relaxation times of extensor digitorum longus muscles (132). This suggests that Hippo signalling affects muscle fibre type-specific gene expression and fibre type percentages.

### **Hippo and skeletal muscle hypertrophy**

Muscle hypertrophy is a key response to resistance exercise. After resistance exercise, protein synthesis and protein breakdown both increase. In the fed state, protein synthesis is higher than breakdown, resulting in protein accretion and hypertrophy (128). However, the effect of resistance exercise on muscle hypertrophy and strength differs greatly among the human population (64). A key mediator of muscle protein synthesis is mTOR signalling, as shown for example by the inhibitory effect of rapamycin on the increase of muscle protein synthesis after resistance exercise in human muscles (30). The key effect of resistance exercise on muscles is mechanical loading, which was discussed in the first part of this review along with the extensive links between mechanosensing and Hippo signalling (reviewed in (50, 87)), including the Z-disc located Bag3 mechanosensor in skeletal muscle (135, 136).

Several studies support a link between Hippo signalling, resistance exercise and muscle fibre size. In the first study on Hippo signalling in relation to exercise, the Booth group used chronic stretch overload to induce hypertrophy of the anterior latissimus dorsi muscle and found an increased expression of the skeletal  $\alpha$ -actin gene. They showed that stretch overload activated a CATTCC (MCAT) motif-containing luciferase reporter, suggesting that



Tead transcription factor activity was present during mechanical overload of skeletal muscle (19). In a human study, eight men performed 100 unilateral maximal drop jumps followed by submaximal jumping until exhaustion (75). The mRNA of the Hippo pathway marker genes cysteine-rich angiogenic protein 61 (CYR61) and connective tissue growth factor (CTGF) (77, 164) increased 14- and 2.5-fold 30 min after exercise, respectively. Additionally, CYR61 protein levels were approximately 2-fold higher at both 30 min and 48 h after the exercise compared with resting control levels. This suggests that some forms of mechanical loading can induce the expression of Hippo marker genes. However, it is unclear whether the increases of CYR61 and CTGF expression are a direct consequence of altered Hippo signalling.

Two recent studies linked Yap activity directly to muscle fibre hypertrophy. Watt in the Harvey group used an adeno-associated viral vector (rAAV6)-mediated shRNA knock down strategy to reduce Yap levels in mouse limb muscles. They found a decreased muscle fibre size and reduced protein synthesis (148). Additionally, they used the same rAAV6 system to over express the predominant YAP isoform in muscle and found increases in muscle mass, cross sectional area and protein synthesis (Table 1, (148)). Intriguingly, despite the extensive evidence of cross-talk between Hippo and mTOR signalling discussed in the first part of this review, their YAP interventions did not seem to affect mTOR activity. In another study, the Hornberger group reported that YAP expression increases up to approximately 4.5 folds in the hypertrophying plantaris muscle days synergist ablation, a model commonly used to induce skeletal muscle hypertrophy (46). Then, they used electroporation to overexpress YAP in the tibialis anterior muscles and analysed the muscles 7 days later. The fibres overexpressing YAP were larger than control fibres, demonstrating that elevated YAP activity could cause hypertrophy (**Table 1**). Additionally, they found that YAP induced MyoD and Myc reporters, whilst inhibiting a Smad binding element (CAGA)-containing reporter (46). Reductions in myostatin produce a similar effect on a Smad binding element (CAGA) reporter (166), and a myostatin knock out also induces muscle hypertrophy (95). In

summary, Hippo members can affect fibre type proportions and increased levels of Yap can induce skeletal muscle hypertrophy. Additionally, Hippo marker genes increase after resistance exercise in human skeletal muscle.

### **Hippo and satellite cells**

Satellite cells were discovered by Mauro using electron microscopy (92) and are now well-recognized as the resident stem cells of skeletal muscle (115). The key tool allowing to characterise their function *in vivo* was the Pax7-DTA knockout mice line, which is used to specifically deplete the satellite cell pool in mouse muscles. Studies with these mice showed that satellite cells are essential for the regeneration of skeletal muscle after injury (2, 81, 107), suggesting that, in a sports context, satellite cells are needed to regenerate the muscles damaged by eccentric exercises, such as marathon running (59). In contrast, satellite cell-depleted muscles show a normal hypertrophic response to overload in the short term (93). However, satellite cell-depleted muscle cannot maintain the initial hypertrophy after more than 8 weeks (38), suggesting that satellite cells are essential for muscle regeneration after injury and are required to maintain the size of hypertrophied muscles in the long term.

Hippo members are key mediators of proliferation and differentiation in satellite cells and myoblasts (mononuclear muscle cells). Yap is active in proliferating C2C12 myoblasts, and high Yap activity promotes their proliferation but inhibits myogenic differentiation (147). In satellite cells, Yap protein levels are low in the quiescent state, but increase when satellite cells become activated and develop into MyoD-expressing myoblasts. Again, high Yap activity resulting from the expression of the constitutively active *YAP1 S127A* mutant promotes proliferation but inhibits differentiation (67). Conversely, knocking down Yap in satellite cell-derived myoblasts reduces proliferation by approximately 40% (67). The overexpression of *YAP1 S127A* in satellite cell-derived myoblasts also increases the expression of proliferation-associated genes and known satellite cell regulators, such as

BMP4 (109) and CD34 (4), while reducing the expression of differentiation markers and the myogenic differentiation regulator Mrf4 (67). Collectively, these results indicate that Yap promotes myoblast and satellite cell proliferation but inhibits differentiation into myotubes and muscle fibres. This suggests that Yap might be an important regulator of muscle development (myogenesis) and satellite cell-derived myoblasts proliferation after injury and in response to hypertrophy. The requirement of Yap and other Hippo members, such as Taz, during the satellite cells response to exercise remains to be formally demonstrated.

### **Hippo and the Athlete's heart**

The maximal oxygen uptake ( $\text{VO}_2\text{max}$ ) is the key determinant of an individual's endurance capacity (27) and is also associated with longevity (15). Early physiological studies in humans demonstrated that one of the key predictors of an individual's  $\text{VO}_2\text{max}$  is the blood flow generated by the heart, termed cardiac output (99), which determines the efficiency of oxygen transport to the exercising musculature. The  $\text{VO}_2\text{max}$  and cardiac output parameters respond to exercise training and detraining, as demonstrated by Saltin and colleagues (113). They showed that 20 days of bed rest reduces resting heart volume by approximately 10% and exercise cardiac output by 15%, resulting in a significantly reduced  $\text{VO}_2\text{max}$  (113). Conversely, 55 days of endurance exercise training following the bed rest increased cardiac output above pre-bed rest levels. This partially explains the restoration of  $\text{VO}_2\text{max}$  (142).

The increase in cardiac output can be attributed to the development of an athlete's heart in response to endurance training. Indeed, electrocardiographic studies show that athletes have enlarged hearts (9) which was later confirmed by comparative echocardiography on endurance athletes (91). Generally, the main cellular mechanism underlying the athlete's heart is cardiomyocyte hypertrophy. For example endurance running training for 8 weeks increases cardiomyocyte size by 17-32% in mice (73). Until several years ago, researchers thought that adult cardiomyocytes were unable to proliferate and regenerate the heart. However, this view is now changing (33). By determining the levels of  $^{14}\text{C}$  DNA integration

from nuclear bomb tests, Bergmann et al. estimated that between 0.45 and 1% of human cardiomyocytes renew per annum. Furthermore, they showed that by the age of 50, 40% of the cardiomyocytes had emerged after birth (14). Moreover, swim endurance training for 2 weeks increased the expression of proliferation markers in mouse cardiomyocytes (16), suggesting that exercise promotes cardiomyocytes proliferation, at least in mice. There is emerging evidence supporting the existence of a cardiac stem cell population that may engage in some limited regeneration processes (32) in addition to a low rate renewal of pre-existing cardiomyocytes (119). Two recent studies found that both cardiac stem cells and cardiomyocytes proliferate in response to endurance exercise in rodents (80, 146). Collectively, these data demonstrate that endurance exercise increases left ventricular volume, thickness and pumping performance and suggest that these effects occur mainly through cardiomyocyte hypertrophy with a limited contribution of cardiac stem cells and cardiomyocytes proliferation. Consequently, this results in the development of the athlete's heart, which in turn increases the  $VO_{2max}$  and aerobic exercise capacity of an individual.

The heart can respond to increased load in two different ways, depending upon the nature of the load (94):

- 1) **Physiological hypertrophy** (i.e., athlete's heart) can occur as a response to endurance exercise or pregnancy (volumetric hypertrophy) or resistance exercise (non-volumetric hypertrophy);
- 2) **Pathological hypertrophy** can occur after cardiac injury or in individuals with high blood pressure or defective valves.

Physiological hypertrophy, which is associated with exercise or pregnancy, differs from pathological hypertrophy by the nature of the stimuli, the structural response, the absence of fibrosis and the molecular drivers leading to the adaptation (94). Generally, physiological hypertrophy does not progress into cardiac dysfunction. In contrast, pathological hypertrophy often decompensates, reducing cardiac function and resulting in end-stage heart failure (72).

Both types of hypertrophy differ at the molecular level in their response the divergent stimuli (1).

Currently, whether and how Hippo signalling contributes to the different forms of cardiac hypertrophy remains incompletely understood. Several studies show that Yap loss- or gain-of-function in the embryonic heart is frequently lethal (reviewed by (84, 141, 155)). This suggests that normal Yap function is essential for normal cardiac development. Presumably, Yap is active only in certain cell populations during specific periods, which could explain why permanent Yap gain- or loss-of-function has such a detrimental effect. There is some evidence that Hippo signalling is perturbed during pathological cardiac hypertrophy. Yap is expressed at higher levels and dephosphorylated (activated) in samples obtained from pathologically hypertrophied human hearts (144). Furthermore, Yap is activated in hearts stressed by pathological pressure overload (144) and in the area bordering a myocardial infarction in mice (25).

Are Hippo members contributing to the formation of the athlete's heart in response to exercise? Although this question has not been addressed directly, published data suggest possible roles for Hippo members in mediating the athlete's heart (see also **Table 1**). First, *Yap1* overexpression in cultured neonatal rat cardiomyocytes promotes hypertrophy and survival compared to control cardiomyocytes (25). In contrast, two other teams reported no cardiomyocyte hypertrophy upon Yap activation in postnatal mouse hearts *in vivo* (139, 154). The reasons behind these contrasting results are unknown and so it is unclear whether Hippo signalling contributes to cardiomyocyte hypertrophy in response to exercise (73).

Another response of the heart to endurance exercise is the limited proliferation of cardiomyocytes and cardiac stem cells in rodents (16, 80, 146). While it has not been tested whether Hippo members promote cardiomyocyte or cardiac stem cell proliferation in response to endurance exercise, evidence supporting that Hippo members regulate the

proliferation of adult cardiomyocytes and can enhance regeneration after cardiac injury has been reported (**Table 1**). Knocking out the Hippo members *Sav1* or *Lats1/2* in adult mouse cardiomyocytes increases proliferation, promotes regeneration after myocardial infarction and reduces scar tissue formation (58). Similarly, *Yap1 S112A* overexpression in cardiomyocytes improves cardiac regeneration after myocardial infarction, both in neonatal and adult mice, with evidence for increased cardiomyocyte proliferation compared to controls (154). Finally, in a mouse model of myocardial infarction, forcing human YAP expression in the heart using adeno-associated virus delivery increases cardiomyocyte proliferation and improves cardiac function as well as survival (85).

In summary, the normal function of Yap and Hippo signalling is essential for normal cardiac development. Currently, it is unknown whether Hippo members and Yap in cardiomyocytes and cardiac stem cells respond to exercise and contribute to the development of an athlete's heart. Available studies suggest that Yap can promote cardiomyocyte hypertrophy in some contexts, while, in other contexts, Yap appears to promote cardiomyocyte proliferation and enhance cardiac regeneration after injury.

### **Hippo & body height**

Body height is a key factor in sports, which is most striking in NBA basketball players. Body height is approximately 70-90% inherited (121) and depends on hundreds, if not thousands, of common DNA sequence variations with a small effect size (152). In rare cases, body height can be affected by single, rare mutations with a large effect size. Examples for the latter are dwarfism caused by *FGFR3* mutations (37), and acromegaly resulting from *AIP* gene mutations (20).

Given that a core function of Hippo signalling is to control cell numbers, one would expect links between Hippo gene DNA sequence variations and body height. Interestingly, genome-wide association studies (GWAS) involving the analysis of data from up to 250,000

individuals (152) show that single nucleotide polymorphisms (SNPs) in several Hippo genes are associated with body height (23, 78, 152). Indeed, SNPs associated with genes encoding for *LATS2*, *TEAD1*, *YAP1*, *VGLL2*, *VGLL3*, and *VGLL4* are associated with body height (23, 57, 78, 152). In the largest meta-analysis study using data obtained from 253,288 individuals of recent European ancestry (152), body height-associated SNPs in *LATS2* (rs1199734), *TEAD1* (rs6485978, rs2099745), *VGLL2* (rs1405212) and *VGLL4* (rs13078528) were identified. In 2010, Lango Allen et al. identified an association between SNPs in *TEAD1* (rs7926971) and *VGLL2* (rs961764) with body height in 133,653 individuals of recent European ancestry. Also, SNPs in *YAP1* (rs11225148) and in *VGLL3* (rs7628864) were individually associated with a shorter stature during pubertal growth in a longitudinal meta-analysis involving 18,737 European individuals (23). Interestingly, the SNP in *VGLL3* was only significantly associated with the trait in females. So far, no sex-related differences were reported for the Hippo pathway functions but this association could suggest that such differences might actually exist in some contexts. Finally, a SNP in *VGLL4* (rs6772112) was associated with height in 36,227 East Asian ancestry subjects (57). Another interesting association of the study by Cousminer et al. is the identification of a female-specific SNP in *LIN28B* associated with late pubertal growth (23). The *LIN28/LET-7* pathway, which has recently emerged as a potent regulator of organismal development and cellular metabolism (120), has been functionally linked with the Hippo pathway (21, 104). In summary, common DNA sequence variants in several Hippo genes influence body height but the effect of each variant on height is small, presumably as *de novo* DNA sequence variants with a large effect size either become fixed or lost relatively quickly (17).

## **Summary and future research**

In this review, we have listed mainly indirect evidence suggesting that Hippo signalling may mediate some of the physiological adaptations to exercise and that SNPs, especially in the Hippo transcriptional regulators, are associated with body height as a measure of whole

549 body cell numbers. The task for molecular exercise physiologists is now to directly show that  
550 these mechanisms mediate adaptation to exercise in exercise models and that Hippo gene  
551 variants are associated with sport and exercise-related traits. We end with three questions:

552 1) Because resistance and endurance exercise trigger different adaptations in skeletal  
553 muscle, how can it be explained that the activity of Hippo members is both affected by  
554 both resistance and endurance exercise-associated signals?

555 2) Given that Hippo signalling affects amino acid (52) and glucose transporter expression  
556 (145), can this be used to develop strategies to alter the responsiveness to nutrients?  
557 For example, can we target through Hippo modulation the leucine transporter LAT1 (52)  
558 to make muscles and other organs more sensitive to protein intake ? Could such  
559 strategy be beneficial for strength athletes or in cases of muscle weakness and wasting,  
560 for example, in elderly individuals or cancer patients with sarcopenia?

561 3) Given that the Hippo pathway is involved in regulating the fate of many stem cells (129),  
562 can this be exploited to develop interventions aimed at improving the repair of muscle,  
563 tendons and cartilage after sports injury or in degenerative muscle diseases?

564



## **Acknowledgements**

We are grateful to Prof Anna Krook (Karolinska Institute), Prof Jörg Höhfeld (University of Bonn) and Dr Carsten G Hansen (University of Edinburgh) for their comments on this review. Work in the Aberdeen Hippo lab is funded by the Medical Research Council (grant number 99477), Sarcoma UK and Friends of Anchor. AMT is recipient of a postdoctoral fellowship from the Canadian Institutes of Health Research (CIHR).

## **Grants**

BMG is supported by a Wenner-Gren Foundation Postdoctoral Fellowship, a European Foundation for the Study of Diabetes (EFSD) Albert Renold Travel Fellowship and a Novo Nordisk Foundation Challenge Grant. AMT is recipient of a postdoctoral fellowship from the Canadian Institutes of Health Research (CIHR). Work in the Aberdeen Hippo lab is funded by the Medical Research Council (grant number 99477), Sarcoma UK and Friends of Anchor.

## **Disclosure Statement**

We have no conflicts of interest to disclose.

## References

1. **Abel ED, and Doenst T.** Mitochondrial adaptations to physiological vs. pathological cardiac hypertrophy. *Cardiovasc Res* 90: 234-242, 2011.
2. **Abou-Khalil R, Yang F, Lieu S, Julien A, Perry J, Pereira C, Relaix F, Miclau T, Marcucio R, and Colnot C.** Role of muscle stem cells during skeletal regeneration. *Stem cells* 33: 1501-1511, 2015.
3. **Alarcon C, Zaromytidou AI, Xi Q, Gao S, Yu J, Fujisawa S, Barlas A, Miller AN, Manova-Todorova K, Macias MJ, Sapkota G, Pan D, and Massague J.** Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways. *Cell* 139: 757-769, 2009.
4. **Alfaro LA, Dick SA, Siegel AL, Anonuevo AS, McNagny KM, Megeney LA, Cornelison DD, and Rossi FM.** CD34 promotes satellite cell motility and entry into proliferation to facilitate efficient skeletal muscle regeneration. *Stem cells* 29: 2030-2041, 2011.
5. **Ameln H, Gustafsson T, Sundberg CJ, Okamoto K, Jansson E, Poellinger L, and Makino Y.** Physiological activation of hypoxia inducible factor-1 in human skeletal muscle. *FASEB J* 19: 1009-1011, 2005.
6. **Anbanandam A, Albarado DC, Nguyen CT, Halder G, Gao X, and Veeraraghavan S.** Insights into transcription enhancer factor 1 (TEF-1) activity from the solution structure of the TEA domain. *ProcNatlAcadSciUSA* 103: 17225-17230, 2006.
7. **Aragon E, Goerner N, Xi Q, Gomes T, Gao S, Massague J, and Macias MJ.** Structural basis for the versatile interactions of Smad7 with regulator WW domains in TGF-beta Pathways. *Structure* 20: 1726-1736, 2012.
8. **Aragona M, Panciera T, Manfrin A, Giulitti S, Michielin F, Elvassore N, Dupont S, and Piccolo S.** A Mechanical Checkpoint Controls Multicellular Growth through YAP/TAZ Regulation by Actin-Processing Factors. *Cell* 2013.
9. **Arstila M, and Koivikko A.** Electrocardiographic and vectorcardiographic signs of left and right ventricular hypertrophy in endurance athletes. *J Sports Med Phys Fitness* 6: 166-175, 1966.

- 612 10. **Atherton PJ, Smith K, Etheridge T, Rankin D, and Rennie MJ.** Distinct anabolic  
613 signalling responses to amino acids in C2C12 skeletal muscle cells. *AminoAcids* 38: 1533-  
614 1539, 2010.
- 615 11. **Baar K, and Esser K.** Phosphorylation of p70(S6k) correlates with increased skeletal  
616 muscle mass following resistance exercise. *AmJPhysiol* 276: C120-C127, 1999.
- 617 12. **Bartlett JD, Hawley JA, and Morton JP.** Carbohydrate availability and exercise  
618 training adaptation: too much of a good thing? *European journal of sport science* 15: 3-12,  
619 2015.
- 620 13. **Basu S, Totty NF, Irwin MS, Sudol M, and Downward J.** Akt phosphorylates the  
621 Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-  
622 mediated apoptosis. *MolCell* 11: 11-23, 2003.
- 623 14. **Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabe-Heider F, Walsh S,**  
624 **Zupicich J, Alkass K, Buchholz BA, Druid H, Jovinge S, and Frisen J.** Evidence for  
625 cardiomyocyte renewal in humans. *Science* 324: 98-102, 2009.
- 626 15. **Blair SN, Kampert JB, Kohl HW, 3rd, Barlow CE, Macera CA, Paffenbarger RS,**  
627 **Jr., and Gibbons LW.** Influences of cardiorespiratory fitness and other precursors on  
628 cardiovascular disease and all-cause mortality in men and women. *JAMA* 276: 205-210,  
629 1996.
- 630 16. **Bostrom P, Mann N, Wu J, Quintero PA, Plovie ER, Panakova D, Gupta RK,**  
631 **Xiao C, MacRae CA, Rosenzweig A, and Spiegelman BM.** C/EBPbeta controls exercise-  
632 induced cardiac growth and protects against pathological cardiac remodeling. *Cell* 143:  
633 1072-1083, 2010.
- 634 17. **Bouchard C.** Exercise genomics-a paradigm shift is needed: a commentary. *British*  
635 *journal of sports medicine* 49: 1492-1496, 2015.
- 636 18. **Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R, and**  
637 **Brummelkamp TR.** YAP1 increases organ size and expands undifferentiated progenitor  
638 cells. *CurrBiol* 17: 2054-2060, 2007.
- 639 19. **Carson JA, Schwartz RJ, and Booth FW.** SRF and TEF-1 control of chicken  
640 skeletal alpha-actin gene during slow-muscle hypertrophy. *AmJPhysiol* 270: C1624-C1633,  
641 1996.

- 642 20. **Chahal HS, Stals K, Unterlander M, Balding DJ, Thomas MG, Kumar AV, Besser**  
643 **GM, Atkinson AB, Morrison PJ, Howlett TA, Levy MJ, Orme SM, Akker SA, Abel RL,**  
644 **Grossman AB, Burger J, Ellard S, and Korbonits M.** AIP mutation in pituitary adenomas  
645 in the 18th century and today. *N Engl J Med* 364: 43-50, 2011.
- 646 21. **Chaulk SG, Lattanzi VJ, Hiemer SE, Fahlman RP, and Varelas X.** The Hippo  
647 pathway effectors TAZ/YAP regulate dicer expression and microRNA biogenesis through  
648 Let-7. *The Journal of biological chemistry* 289: 1886-1891, 2014.
- 649 22. **Cinar B, Fang PK, Lutchman M, Di VD, Adam RM, Pavlova N, Rubin MA, Yelick**  
650 **PC, and Freeman MR.** The pro-apoptotic kinase Mst1 and its caspase cleavage products  
651 are direct inhibitors of Akt1. *EMBO J* 26: 4523-4534, 2007.
- 652 23. **Cousminer DL, Berry DJ, Timpson NJ, Ang W, Thiering E, Byrne EM, Taal HR,**  
653 **Huikari V, Bradfield JP, Kerkhof M, Groen-Blokhuis MM, Kreiner-Moller E, Marinelli M,**  
654 **Holst C, Leinonen JT, Perry JR, Surakka I, Pietilainen O, Kettunen J, Anttila V,**  
655 **Kaakinen M, Sovio U, Pouta A, Das S, Lagou V, Power C, Prokopenko I, Evans DM,**  
656 **Kemp JP, St Pourcain B, Ring S, Palotie A, Kajantie E, Osmond C, Lehtimäki T, Viikari**  
657 **JS, Kahonen M, Warrington NM, Lye SJ, Palmer LJ, Tiesler CM, Flexeder C,**  
658 **Montgomery GW, Medland SE, Hofman A, Hakonarson H, Guxens M, Bartels M,**  
659 **Salomaa V, ReproGen C, Murabito JM, Kaprio J, Sorensen TI, Ballester F, Bisgaard H,**  
660 **Boomsma DI, Koppelman GH, Grant SF, Jaddoe VW, Martin NG, Heinrich J, Pennell**  
661 **CE, Raitakari OT, Eriksson JG, Smith GD, Hyppönen E, Jarvelin MR, McCarthy MI,**  
662 **Ripatti S, Widen E, and Early Growth Genetics C.** Genome-wide association and  
663 longitudinal analyses reveal genetic loci linking pubertal height growth, pubertal timing and  
664 childhood adiposity. *Human molecular genetics* 22: 2735-2747, 2013.
- 665 24. **Davidson I, Xiao JH, Rosales R, Staub A, and Chambon P.** The HeLa cell protein  
666 TEF-1 binds specifically and cooperatively to two SV40 enhancer motifs of unrelated  
667 sequence. *Cell* 54: 931-942, 1988.
- 668 25. **Del Re DP, Yang Y, Nakano N, Cho J, Zhai P, Yamamoto T, Zhang N, Yabuta N,**  
669 **Nojima H, Pan D, and Sadoshima J.** Yes-associated protein isoform 1 (Yap1) promotes  
670 cardiomyocyte survival and growth to protect against myocardial ischemic injury. *JBiolChem*  
671 288: 3977-3988, 2013.
- 672 26. **DeRan M, Yang J, Shen CH, Peters EC, Fitamant J, Chan P, Hsieh M, Zhu S,**  
673 **Asara JM, Zheng B, Bardeesy N, Liu J, and Wu X.** Energy Stress Regulates Hippo-YAP

674 Signaling Involving AMPK-Mediated Regulation of Angiotensin-like 1 Protein. *Cell reports* 9:  
675 495-503, 2014.

676 27. **di Prampero PE.** Factors limiting maximal performance in humans. *Eur J Appl*  
677 *Physiol* 90: 420-429, 2003.

678 28. **Dickinson JM, Fry CS, Drummond MJ, Gundermann DM, Walker DK, Glynn EL,**  
679 **Timmerman KL, Dhanani S, Volpi E, and Rasmussen BB.** Mammalian target of  
680 rapamycin complex 1 activation is required for the stimulation of human skeletal muscle  
681 protein synthesis by essential amino acids. *JNutr* 141: 856-862, 2011.

682 29. **Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF,**  
683 **Anders RA, Maitra A, and Pan D.** Elucidation of a universal size-control mechanism in  
684 *Drosophila* and mammals. *Cell* 130: 1120-1133, 2007.

685 30. **Drummond MJ, Fry CS, Glynn EL, Dreyer HC, Dhanani S, Timmerman KL, Volpi**  
686 **E, and Rasmussen BB.** Rapamycin administration in humans blocks the contraction-  
687 induced increase in skeletal muscle protein synthesis. *JPhysiol* 587: 1535-1546, 2009.

688 31. **Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, Zanconato F,**  
689 **Le DJ, Forcato M, Bicciato S, Elvassore N, and Piccolo S.** Role of YAP/TAZ in  
690 mechanotransduction. *Nature* 474: 179-183, 2011.

691 32. **Ellison GM, Vicinanza C, Smith AJ, Aquila I, Leone A, Waring CD, Henning BJ,**  
692 **Stirparo GG, Papait R, Scarfo M, Agosti V, Viglietto G, Condorelli G, Indolfi C,**  
693 **Ottolenghi S, Torella D, and Nadal-Ginard B.** Adult c-kit(pos) cardiac stem cells are  
694 necessary and sufficient for functional cardiac regeneration and repair. *Cell* 154: 827-842,  
695 2013.

696 33. **Ellison GM, Waring CD, Vicinanza C, and Torella D.** Physiological cardiac  
697 remodelling in response to endurance exercise training: cellular and molecular mechanisms.  
698 *Heart* 98: 5-10, 2012.

699 34. **Engler AJ, Griffin MA, Sen S, Bonnemann CG, Sweeney HL, and Discher DE.**  
700 Myotubes differentiate optimally on substrates with tissue-like stiffness: pathological  
701 implications for soft or stiff microenvironments. *JCell Biol* 166: 877-887, 2004.

702 35. **Engler AJ, Sen S, Sweeney HL, and Discher DE.** Matrix elasticity directs stem cell  
703 lineage specification. *Cell* 126: 677-689, 2006.

- 704 36. **Enzo E, Santinon G, Pocaterra A, Aragona M, Bresolin S, Forcato M, Grifoni D,**  
705 **Pession A, Zanconato F, Guzzo G, Bicciato S, and Dupont S.** Aerobic glycolysis tunes  
706 YAP/TAZ transcriptional activity. *The EMBO journal* 2015.
- 707 37. **Foldynova-Trantirkova S, Wilcox WR, and Krejci P.** Sixteen years and counting:  
708 the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal  
709 dysplasias. *Human mutation* 33: 29-41, 2012.
- 710 38. **Fry CS, Lee JD, Jackson JR, Kirby TJ, Stasko SA, Liu H, Dupont-Versteegden**  
711 **EE, McCarthy JJ, and Peterson CA.** Regulation of the muscle fiber microenvironment by  
712 activated satellite cells during hypertrophy. *FASEB journal : official publication of the*  
713 *Federation of American Societies for Experimental Biology* 28: 1654-1665, 2014.
- 714 39. **Galli GG, Carrara M, Yuan WC, Valdes-Quezada C, Gurung B, Pepe-Mooney B,**  
715 **Zhang T, Geeven G, Gray NS, de Laat W, Calogero RA, and Camargo FD.** YAP Drives  
716 Growth by Controlling Transcriptional Pause Release from Dynamic Enhancers. *Molecular*  
717 *cell* 60: 328-337, 2015.
- 718 40. **Gateff E.** Malignant neoplasms of genetic origin in *Drosophila melanogaster*. *Science*  
719 200: 1448-1459, 1978.
- 720 41. **Gilbert PM, Havenstrite KL, Magnusson KE, Sacco A, Leonardi NA, Kraft P,**  
721 **Nguyen NK, Thrun S, Lutolf MP, and Blau HM.** Substrate elasticity regulates skeletal  
722 muscle stem cell self-renewal in culture. *Science* 329: 1078-1081, 2010.
- 723 42. **Goldberg AL, Etlinger JD, Goldspink DF, and Jablecki C.** Mechanism of work-  
724 induced hypertrophy of skeletal muscle. *MedSciSports* 7: 185-198, 1975.
- 725 43. **Gollnick PD, Armstrong RB, Saltin B, Saubert CW, Sembrowich WL, and**  
726 **Shepherd RE.** Effect of training on enzyme activity and fiber composition of human skeletal  
727 muscle. *JApplPhysiol* 34: 107-111, 1973.
- 728 44. **Gollnick PD, Armstrong RB, Saubert CW, Piehl K, and Saltin B.** Enzyme activity  
729 and fiber composition in skeletal muscle of untrained and trained men. *JApplPhysiol* 33: 312-  
730 319, 1972.
- 731 45. **Gollnick PD, Piehl K, and Saltin B.** Selective glycogen depletion pattern in human  
732 muscle fibres after exercise of varying intensity and at varying pedalling rates. *JPhysiol* 241:  
733 45-57, 1974.

- 734 46. **Goodman CA, Dietz JM, Jacobs BL, McNally RM, You JS, and Hornberger TA.**  
 735 Yes-Associated Protein is up-regulated by mechanical overload and is sufficient to induce  
 736 skeletal muscle hypertrophy. *FEBS letters* 589: 1491-1497, 2015.
- 737 47. **Gordon SE, Davis BS, Carlson CJ, and Booth FW.** ANG II is required for optimal  
 738 overload-induced skeletal muscle hypertrophy. *AmJPhysiol EndocrinolMetab* 280: E150-  
 739 E159, 2001.
- 740 48. **Grobet L, Martin LJ, Poncelet D, Pirottin D, Brouwers B, Riquet J, Schoeberlein**  
 741 **A, Dunner S, Menissier F, Massabanda J, Fries R, Hanset R, and Georges M.** A deletion  
 742 in the bovine myostatin gene causes the double-muscling phenotype in cattle. *NatGenet* 17:  
 743 71-74, 1997.
- 744 49. **Guo J, Kleeff J, Zhao Y, Li J, Giese T, Esposito I, Buchler MW, Korc M, and**  
 745 **Friess H.** Yes-associated protein (YAP65) in relation to Smad7 expression in human  
 746 pancreatic ductal adenocarcinoma. *IntJMolMed* 17: 761-767, 2006.
- 747 50. **Halder G, Dupont S, and Piccolo S.** Transduction of mechanical and cytoskeletal  
 748 cues by YAP and TAZ. *NatRevMolCell Biol* 13: 591-600, 2012.
- 749 51. **Hansen CG, Moroishi T, and Guan KL.** YAP and TAZ: a nexus for Hippo signaling  
 750 and beyond. *Trends in cell biology* 2015.
- 751 52. **Hansen CG, Ng YL, Lam WL, Plouffe SW, and Guan KL.** The Hippo pathway  
 752 effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1.  
 753 *Cell research* 25: 1299-1313, 2015.
- 754 53. **Hardie DG.** AMPK: positive and negative regulation, and its role in whole-body  
 755 energy homeostasis. *Current opinion in cell biology* 33: 1-7, 2015.
- 756 54. **Hardie DG.** Energy sensing by the AMP-activated protein kinase and its effects on  
 757 muscle metabolism. *ProcNutrSoc* 70: 92-99, 2011.
- 758 55. **Hardie DG, and Ashford ML.** AMPK: regulating energy balance at the cellular and  
 759 whole body levels. *Physiology* 29: 99-107, 2014.
- 760 56. **Harvey K, and Tapon N.** The Salvador-Warts-Hippo pathway - an emerging tumour-  
 761 suppressor network. *NatRevCancer* 7: 182-191, 2007.
- 762 57. **He M, Xu M, Zhang B, Liang J, Chen P, Lee JY, Johnson TA, Li H, Yang X, Dai J,**  
 763 **Liang L, Gui L, Qi Q, Huang J, Li Y, Adair LS, Aung T, Cai Q, Cheng CY, Cho MC, Cho**

764 **YS, Chu M, Cui B, Gao YT, Go MJ, Gu D, Gu W, Guo H, Hao Y, Hong J, Hu Z, Hu Y,**  
765 **Huang J, Hwang JY, Ikram MK, Jin G, Kang DH, Khor CC, Kim BJ, Kim HT, Kubo M,**  
766 **Lee J, Lee J, Lee NR, Li R, Li J, Liu J, Longe J, Lu W, Lu X, Miao X, Okada Y, Ong RT,**  
767 **Qiu G, Seielstad M, Sim X, Song H, Takeuchi F, Tanaka T, Taylor PR, Wang L, Wang W,**  
768 **Wang Y, Wu C, Wu Y, Xiang YB, Yamamoto K, Yang H, Liao M, Yokota M, Young T,**  
769 **Zhang X, Kato N, Wang QK, Zheng W, Hu FB, Lin D, Shen H, Teo YY, Mo Z, Wong TY,**  
770 **Lin X, Mohlke KL, Ning G, Tsunoda T, Han BG, Shu XO, Tai ES, Wu T, and Qi L.** Meta-  
771 analysis of genome-wide association studies of adult height in East Asians identifies 17  
772 novel loci. *Human molecular genetics* 24: 1791-1800, 2015.

773 58. **Heallen T, Morikawa Y, Leach J, Tao G, Willerson JT, Johnson RL, and Martin**  
774 **JF.** Hippo signaling impedes adult heart regeneration. *Development* 140: 4683-4690, 2013.

775 59. **Hikida RS, Staron RS, Hagerman FC, Sherman WM, and Costill DL.** Muscle fiber  
776 necrosis associated with human marathon runners. *JNeuroSci* 59: 185-203, 1983.

777 60. **Hilman D, and Gat U.** The evolutionary history of YAP and the hippo/YAP pathway.  
778 *Molecular biology and evolution* 28: 2403-2417, 2011.

779 61. **Hoffman NJ, Parker BL, Chaudhuri R, Fisher-Wellman KH, Kleinert M,**  
780 **Humphrey SJ, Yang P, Holliday M, Trefely S, Fazakerley DJ, Stockli J, Burchfield JG,**  
781 **Jensen TE, Jothi R, Kiens B, Wojtaszewski JF, Richter EA, and James DE.** Global  
782 Phosphoproteomic Analysis of Human Skeletal Muscle Reveals a Network of Exercise-  
783 Regulated Kinases and AMPK Substrates. *Cell metabolism* 2015.

784 62. **Homma S, Iwasaki M, Shelton GD, Engvall E, Reed JC, and Takayama S.** BAG3  
785 deficiency results in fulminant myopathy and early lethality. *AmJPathol* 169: 761-773, 2006.

786 63. **Huang J, Wu S, Barrera J, Matthews K, and Pan D.** The Hippo signaling pathway  
787 coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila  
788 Homolog of YAP. *Cell* 122: 421-434, 2005.

789 64. **Hubal MJ, Gordish-Dressman H, Thompson PD, Price TB, Hoffman EP,**  
790 **Angelopoulos TJ, Gordon PM, Moyna NM, Pescatello LS, Visich PS, Zoeller RF, Seip**  
791 **RL, and Clarkson PM.** Variability in muscle size and strength gain after unilateral resistance  
792 training. *MedSciSports Exerc* 37: 964-972, 2005.

793 65. **Jang SW, Yang SJ, Srinivasan S, and Ye K.** Akt phosphorylates Mstl and prevents  
794 its proteolytic activation, blocking FOXO3 phosphorylation and nuclear translocation.  
795 *JBiolChem* 282: 30836-30844, 2007.



- 796 66. **Jiao S, Wang H, Shi Z, Dong A, Zhang W, Song X, He F, Wang Y, Zhang Z,**  
797 **Wang W, Wang X, Guo T, Li P, Zhao Y, Ji H, Zhang L, and Zhou Z.** A Peptide Mimicking  
798 VGLL4 Function Acts as a YAP Antagonist Therapy against Gastric Cancer. *Cancer cell* 25:  
799 166-180, 2014.
- 800 67. **Judson RN, Tremblay AM, Knopp P, White RB, Urcia R, De Bari C, Zammit PS,**  
801 **Camargo FD, and Wackerhage H.** The Hippo pathway member Yap plays a key role in  
802 influencing fate decisions in muscle satellite cells. *Journal of cell science* 125: 6009-6019,  
803 2012.
- 804 68. **Justice RW, Zilian O, Woods DF, Noll M, and Bryant PJ.** The Drosophila tumor  
805 suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is  
806 required for the control of cell shape and proliferation. *Genes & development* 9: 534-546,  
807 1995.
- 808 69. **Kambadur R, Sharma M, Smith TP, and Bass JJ.** Mutations in myostatin (GDF8) in  
809 double-musced Belgian Blue and Piedmontese cattle. *Genome Res* 7: 910-916, 1997.
- 810 70. **Kanai F, Marignani PA, Sarbassova D, Yagi R, Hall RA, Donowitz M, Hisaminato**  
811 **A, Fujiwara T, Ito Y, Cantley LC, and Yaffe MB.** TAZ: a novel transcriptional co-activator  
812 regulated by interactions with 14-3-3 and PDZ domain proteins. *EMBO J* 19: 6778-6791,  
813 2000.
- 814 71. **Karasheva N, Tsika G, Ji J, Zhang A, Mao X, and Tsika R.** Transcription enhancer  
815 factor 1 binds multiple muscle MEF2 and A/T-rich elements during fast-to-slow skeletal  
816 muscle fiber type transitions. *Molecular and cellular biology* 23: 5143-5164, 2003.
- 817 72. **Katz AM, and Rolett EL.** Heart failure: when form fails to follow function. *Eur Heart J*  
818 2015.
- 819 73. **Kemi OJ, Loennechen JP, Wisloff U, and Ellingsen O.** Intensity-controlled  
820 treadmill running in mice: cardiac and skeletal muscle hypertrophy. *Journal of applied*  
821 *physiology* 93: 1301-1309, 2002.
- 822 74. **Kim M, Kim M, Lee S, Kuninaka S, Saya H, Lee H, Lee S, and Lim DS.** cAMP/PKA  
823 signalling reinforces the LATS-YAP pathway to fully suppress YAP in response to actin  
824 cytoskeletal changes. *EMBO J* 32: 1543-1555, 2013.
- 825 75. **Kivela R, Kyrolainen H, Selanne H, Komi PV, Kainulainen H, and Vihko V.** A  
826 single bout of exercise with high mechanical loading induces the expression of Cyr61/CCN1

827 and CTGF/CCN2 in human skeletal muscle. *Journal of applied physiology* 103: 1395-1401,  
828 2007.

829 76. **Koontz LM, Liu-Chittenden Y, Yin F, Zheng Y, Yu J, Huang B, Chen Q, Wu S,**  
830 **and Pan D.** The Hippo Effector Yorkie Controls Normal Tissue Growth by Antagonizing  
831 Scalloped-Mediated Default Repression. *DevCell* 25: 388-401, 2013.

832 77. **Lai D, Ho KC, Hao Y, and Yang X.** Taxol resistance in breast cancer cells is  
833 mediated by the hippo pathway component TAZ and its downstream transcriptional targets  
834 Cyr61 and CTGF. *Cancer research* 71: 2728-2738, 2011.

835 78. **Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, Rivadeneira F,**  
836 **Willer CJ, Jackson AU, Vedantam S, Raychaudhuri S, Ferreira T, Wood AR, Weyant**  
837 **RJ, Segre AV, Speliotes EK, Wheeler E, Soranzo N, Park JH, Yang J, Gudbjartsson D,**  
838 **Heard-Costa NL, Randall JC, Qi L, Vernon Smith A, Magi R, Pastinen T, Liang L, Heid**  
839 **IM, Luan J, Thorleifsson G, Winkler TW, Goddard ME, Sin Lo K, Palmer C,**  
840 **Workalemahu T, Aulchenko YS, Johansson A, Zillikens MC, Feitosa MF, Esko T,**  
841 **Johnson T, Ketkar S, Kraft P, Mangino M, Prokopenko I, Absher D, Albrecht E, Ernst F,**  
842 **Glazer NL, Hayward C, Hottenga JJ, Jacobs KB, Knowles JW, Kutalik Z, Monda KL,**  
843 **Polasek O, Preuss M, Rayner NW, Robertson NR, Steinthorsdottir V, Tyrer JP, Voight**  
844 **BF, Wiklund F, Xu J, Zhao JH, Nyholt DR, Pellikka N, Perola M, Perry JR, Surakka I,**  
845 **Tammesoo ML, Altmaier EL, Amin N, Aspelund T, Bhangale T, Boucher G, Chasman**  
846 **DI, Chen C, Coin L, Cooper MN, Dixon AL, Gibson Q, Grundberg E, Hao K, Juhani**  
847 **Junttila M, Kaplan LM, Kettunen J, Konig IR, Kwan T, Lawrence RW, Levinson DF,**  
848 **Lorentzon M, McKnight B, Morris AP, Muller M, Suh Ngwa J, Purcell S, Rafelt S, Salem**  
849 **RM, Salvi E, Sanna S, Shi J, Sovio U, Thompson JR, Turchin MC, Vandenput L,**  
850 **Verlaan DJ, Vitart V, White CC, Ziegler A, Almgren P, Balmforth AJ, Campbell H,**  
851 **Citterio L, De Grandi A, Dominiczak A, Duan J, Elliott P, Elosua R, Eriksson JG,**  
852 **Freimer NB, Geus EJ, Glorioso N, Haiqing S, Hartikainen AL, Havulinna AS, Hicks AA,**  
853 **Hui J, Igl W, Illig T, Julia A, Kajantie E, Kilpelainen TO, Koironen M, Kolcic I, Koskinen**  
854 **S, Kovacs P, Laitinen J, Liu J, Lokki ML, Marusic A, Maschio A, Meitinger T, Mulas A,**  
855 **Pare G, Parker AN, Peden JF, Petersmann A, Pichler I, Pietilainen KH, Pouta A,**  
856 **Ridderstrale M, Rotter JI, Sambrook JG, Sanders AR, Schmidt CO, Sinisalo J, Smit JH,**  
857 **Stringham HM, Bragi Walters G, Widen E, Wild SH, Willemsen G, Zagato L, Zgaga L,**  
858 **Zitting P, Alavere H, Farrall M, McArdle WL, Nelis M, Peters MJ, Ripatti S, van Meurs**  
859 **JB, Aben KK, Ardlie KG, Beckmann JS, Beilby JP, Bergman RN, Bergmann S, Collins**  
860 **FS, Cusi D, den Heijer M, Eiriksdottir G, Gejman PV, Hall AS, Hamsten A, Huikuri HV,**  
861 **Iribarren C, Kahonen M, Kaprio J, Kathiresan S, Kiemeny L, Kocher T, Launer LJ,**

- 862 **Lehtimäki T, Melander O, Mosley TH, Jr., Musk AW, Nieminen MS, O'Donnell CJ,**  
863 **Ohlsson C, Oostra B, Palmer LJ, Raitakari O, Ridker PM, Rioux JD, Rissanen A,**  
864 **Rivolta C, Schunkert H, Shuldiner AR, Siscovick DS, Stumvoll M, Tonjes A,**  
865 **Tuomilehto J, van Ommen GJ, Viikari J, Heath AC, Martin NG, Montgomery GW,**  
866 **Province MA, Kayser M, Arnold AM, Atwood LD, Boerwinkle E, Chanock SJ, Deloukas**  
867 **P, Gieger C, Gronberg H, Hall P, Hattersley AT, Hengstenberg C, Hoffman W, Lathrop**  
868 **GM, Salomaa V, Schreiber S, Uda M, Waterworth D, Wright AF, Assimes TL, Barroso I,**  
869 **Hofman A, Mohlke KL, Boomsma DI, Caulfield MJ, Cupples LA, Erdmann J, Fox CS,**  
870 **Gudnason V, Gyllenstein U, Harris TB, Hayes RB, Jarvelin MR, Mooser V, Munroe PB,**  
871 **Ouweland WH, Penninx BW, Pramstaller PP, Quertermous T, Rudan I, Samani NJ,**  
872 **Spector TD, Volzke H, Watkins H, Wilson JF, Groop LC, Haritunians T, Hu FB, Kaplan**  
873 **RC, Metspalu A, North KE, Schlessinger D, Wareham NJ, Hunter DJ, O'Connell JR,**  
874 **Strachan DP, Wichmann HE, Borecki IB, van Duijn CM, Schadt EE, Thorsteinsdottir U,**  
875 **Peltonen L, Uitterlinden AG, Visscher PM, Chatterjee N, Loos RJ, Boehnke M,**  
876 **McCarthy MI, Ingelsson E, Lindgren CM, Abecasis GR, Stefansson K, Frayling TM, and**  
877 **Hirschhorn JN.** Hundreds of variants clustered in genomic loci and biological pathways  
878 affect human height. *Nature* 467: 832-838, 2010.
- 879 79. **Lee SJ.** Quadrupling muscle mass in mice by targeting TGF-beta signaling  
880 pathways. *PLoS ONE* 2: e789, 2007.
- 881 80. **Leite CF, Lopes CS, Alves AC, Fuzaro CS, Silva MV, Oliveira LF, Garcia LP,**  
882 **Farnesi TS, Cuba MB, Rocha LB, Rodrigues V, Jr., Oliveira CJ, and Dias da Silva VJ.**  
883 Endogenous resident c-Kit cardiac stem cells increase in mice with an exercise-induced,  
884 physiologically hypertrophied heart. *Stem Cell Res* 15: 151-164, 2015.
- 885 81. **Lepper C, Partridge TA, and Fan CM.** An absolute requirement for Pax7-positive  
886 satellite cells in acute injury-induced skeletal muscle regeneration. *Development* 138: 3639-  
887 3646, 2011.
- 888 82. **Li Q, Li S, Mana-Capelli S, Roth Flach RJ, Danai LV, Amcheslavsky A, Nie Y,**  
889 **Kaneko S, Yao X, Chen X, Cotton JL, Mao J, McCollum D, Jiang J, Czech MP, Xu L,**  
890 **and Ip YT.** The conserved misshapen-warts-Yorkie pathway acts in enteroblasts to regulate  
891 intestinal stem cells in *Drosophila*. *Developmental cell* 31: 291-304, 2014.
- 892 83. **Liang N, Zhang C, Dill P, Panasyuk G, Pion D, Koka V, Gallazzini M, Olson EN,**  
893 **Lam H, Henske EP, Dong Z, Apte U, Pallet N, Johnson RL, Terzi F, Kwiatkowski DJ,**  
894 **Scoazec JY, Martignoni G, and Pende M.** Regulation of YAP by mTOR and autophagy

895 reveals a therapeutic target of tuberous sclerosis complex. *The Journal of experimental*  
896 *medicine* 211: 2249-2263, 2014.

897 84. **Lin Z, and Pu WT.** Harnessing Hippo in the heart: Hippo/Yap signaling and  
898 applications to heart regeneration and rejuvenation. *Stem Cell Res* 13: 571-581, 2014.

899 85. **Lin Z, von Gise A, Zhou P, Gu F, Ma Q, Jiang J, Yau AL, Buck JN, Gouin KA,**  
900 **van Gorp PR, Zhou B, Chen J, Seidman JG, Wang DZ, and Pu WT.** Cardiac-specific YAP  
901 activation improves cardiac function and survival in an experimental murine MI model.  
902 *Circulation research* 115: 354-363, 2014.

903 86. **Liu CY, Zha ZY, Zhou X, Zhang H, Huang W, Zhao D, Li T, Chan SW, Lim CJ,**  
904 **Hong W, Zhao S, Xiong Y, Lei QY, and Guan KL.** The hippo tumor pathway promotes TAZ  
905 degradation by phosphorylating a phosphodegron and recruiting the SCF{beta}-TrCP E3  
906 ligase. *JBiolChem* 285: 37159-37169, 2010.

907 87. **Low BC, Pan CQ, Shivashankar G, Bershadsky A, Sudol M, and Sheetz M.** YAP/  
908 TAZ as mechanosensors and mechanotransducers in regulating organ size and tumor  
909 growth. *FEBS letters* 2014.

910 88. **Ma B, Chen Y, Chen L, Cheng H, Mu C, Li J, Gao R, Zhou C, Cao L, Liu J, Zhu Y,**  
911 **Chen Q, and Wu S.** Hypoxia regulates Hippo signalling through the SIAH2 ubiquitin E3  
912 ligase. *Nature cell biology* 17: 95-103, 2015.

913 89. **MacLennan PA, and Edwards RH.** Effects of clenbuterol and propranolol on muscle  
914 mass. Evidence that clenbuterol stimulates muscle beta-adrenoceptors to induce  
915 hypertrophy. *BiochemJ* 264: 573-579, 1989.

916 90. **Mar JH, and Ordahl CP.** A conserved CATTCT motif is required for skeletal  
917 muscle-specific activity of the cardiac troponin T gene promoter. *ProcNatlAcadSciUSA* 85:  
918 6404-6408, 1988.

919 91. **Maron BJ.** Structural features of the athlete heart as defined by echocardiography. *J*  
920 *Am Coll Cardiol* 7: 190-203, 1986.

921 92. **Mauro A.** Satellite cell of skeletal muscle fibers. *JBiochemBiochemCytol* 9: 493-495,  
922 1961.

923 93. **McCarthy JJ, Mula J, Miyazaki M, Erfani R, Garrison K, Farooqui AB, Sriksuea R,**  
924 **Lawson BA, Grimes B, Keller C, Van ZG, Campbell KS, Esser KA, Dupont-Versteegden**

- 925 **EE, and Peterson CA.** Effective fiber hypertrophy in satellite cell-depleted skeletal muscle.  
926 *Development* 138: 3657-3666, 2011.
- 927 94. **McMullen JR, and Jennings GL.** Differences between pathological and  
928 physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure. *Clin Exp*  
929 *Pharmacol Physiol* 34: 255-262, 2007.
- 930 95. **McPherron AC, Lawler AM, and Lee SJ.** Regulation of skeletal muscle mass in  
931 mice by a new TGF-beta superfamily member. *Nature* 387: 83-90, 1997.
- 932 96. **McPherron AC, and Lee SJ.** Double muscling in cattle due to mutations in the  
933 myostatin gene. *ProcNatAcadSciUSA* 94: 12457-12461, 1997.
- 934 97. **Meng Z, Moroishi T, Mottier-Pavie V, Plouffe SW, Hansen CG, Hong AW, Park**  
935 **HW, Mo JS, Lu W, Lu S, Flores F, Yu FX, Halder G, and Guan KL.** MAP4K family kinases  
936 act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway. *Nature communications*  
937 6: 8357, 2015.
- 938 98. **Meyer RA, and Foley JM.** Cellular processes integrating the metabolic response to  
939 exercise. In: *Handbook of Physiology Section 12 Exercise: Regulation and Integration of*  
940 *multiple Systems*, edited by Rowell LB, and Shepherd JT. Oxford: Oxford University Press,  
941 1996, p. 841-869.
- 942 99. **Mitchell JH, Sproule BJ, and Chapman CB.** The physiological meaning of the  
943 maximal oxygen intake test. *J Clin Invest* 37: 538-547, 1958.
- 944 100. **Mo JS, Meng Z, Kim YC, Park HW, Hansen CG, Kim S, Lim DS, and Guan KL.**  
945 Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway.  
946 *Nature cell biology* 17: 500-510, 2015.
- 947 101. **Mohseni M, Sun J, Lau A, Curtis S, Goldsmith J, Fox VL, Wei C, Frazier M,**  
948 **Samson O, Wong KK, Kim C, and Camargo FD.** A genetic screen identifies an LKB1-  
949 MARK signalling axis controlling the Hippo-YAP pathway. *Nature cell biology* 16: 108-117,  
950 2014.
- 951 102. **Moleirinho S, Guerrant W, and Kissil JL.** The Angiomotins - From discovery to  
952 function. *FEBS letters* 2014.
- 953 103. **Montgomery HE, Clarkson P, Dollery CM, Prasad K, Losi MA, Hemingway H,**  
954 **Statters D, Jubb M, Girvain M, Varnava A, World M, Deanfield J, Talmud P, McEwan**

955 **JR, McKenna WJ, and Humphries S.** Association of angiotensin-converting enzyme gene  
 956 I/D polymorphism with change in left ventricular mass in response to physical training.  
 957 *Circulation* 96: 741-747, 1997.

958 104. **Mori M, Triboulet R, Mohseni M, Schlegelmilch K, Shrestha K, Camargo FD, and**  
 959 **Gregory RI.** Hippo signaling regulates microprocessor and links cell-density-dependent  
 960 miRNA biogenesis to cancer. *Cell* 156: 893-906, 2014.

961 105. **Mosher DS, Quignon P, Bustamante CD, Sutter NB, Mellersh CS, Parker HG,**  
 962 **and Ostrander EA.** A mutation in the myostatin gene increases muscle mass and enhances  
 963 racing performance in heterozygote dogs. *PLoSGenet* 3: e79, 2007.

964 106. **Munoz-Canoves P, Scheele C, Pedersen BK, and Serrano AL.** Interleukin-6  
 965 myokine signaling in skeletal muscle: a double-edged sword? *The FEBS journal* 280: 4131-  
 966 4148, 2013.

967 107. **Murphy MM, Lawson JA, Mathew SJ, Hutcheson DA, and Kardon G.** Satellite  
 968 cells, connective tissue fibroblasts and their interactions are crucial for muscle regeneration.  
 969 *Development* 138: 3625-3637, 2011.

970 108. **Nguyen HB, Babcock JT, Wells CD, and Quilliam LA.** LKB1 tumor suppressor  
 971 regulates AMP kinase/mTOR-independent cell growth and proliferation via the  
 972 phosphorylation of Yap. *Oncogene* 32: 4100-4109, 2013.

973 109. **Ono Y, Calhabeu F, Morgan JE, Katagiri T, Amthor H, and Zammit PS.** BMP  
 974 signalling permits population expansion by preventing premature myogenic differentiation in  
 975 muscle satellite cells. *Cell DeathDiffer* 18: 222-234, 2011.

976 110. **Pedersen BK, and Febbraio MA.** Muscle as an endocrine organ: focus on muscle-  
 977 derived interleukin-6. *Physiological reviews* 88: 1379-1406, 2008.

978 111. **Puthucheary Z, Skipworth JR, Rawal J, Loosemore M, Van Someren K, and**  
 979 **Montgomery HE.** The ACE gene and human performance: 12 years on. *Sports medicine*  
 980 41: 433-448, 2011.

981 112. **Sadoshima J, Xu Y, Slayter HS, and Izumo S.** Autocrine release of angiotensin II  
 982 mediates stretch-induced hypertrophy of cardiac myocytes in vitro. *Cell* 75: 977-984, 1993.

983 113. **Saltin B, Blomqvist G, Mitchell JH, Johnson RL, Jr., Wildenthal K, and**  
984 **Chapman CB.** Response to exercise after bed rest and after training. *Circulation* 38: VII1-  
985 78, 1968.

986 114. **Sartori R, Gregorevic P, and Sandri M.** TGFbeta and BMP signaling in skeletal  
987 muscle: potential significance for muscle-related disease. *Trends in endocrinology and*  
988 *metabolism: TEM* 25: 464-471, 2014.

989 115. **Scharner J, and Zammit PS.** The muscle satellite cell at 50: the formative years.  
990 *SkeletMuscle* 1: 28, 2011.

991 116. **Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W, Braun T,**  
992 **Tobin JF, and Lee SJ.** Myostatin mutation associated with gross muscle hypertrophy in a  
993 child. *NEnglJMed* 350: 2682-2688, 2004.

994 117. **Selcen D, Muntoni F, Burton BK, Pegoraro E, Sewry C, Bite AV, and Engel AG.**  
995 Mutation in BAG3 causes severe dominant childhood muscular dystrophy. *AnnNeurol* 65:  
996 83-89, 2009.

997 118. **Semenza GL.** Regulation of oxygen homeostasis by hypoxia-inducible factor 1.  
998 *Physiology* 24: 97-106, 2009.

999 119. **Senyo SE, Steinhauser ML, Pizzimenti CL, Yang VK, Cai L, Wang M, Wu TD,**  
1000 **Guerquin-Kern JL, Lechene CP, and Lee RT.** Mammalian heart renewal by pre-existing  
1001 cardiomyocytes. *Nature* 493: 433-436, 2013.

1002 120. **Shyh-Chang N, and Daley GQ.** Lin28: primal regulator of growth and metabolism in  
1003 stem cells. *Cell stem cell* 12: 395-406, 2013.

1004 121. **Silventoinen K, Sammalisto S, Perola M, Boomsma DI, Cornes BK, Davis C,**  
1005 **Dunkel L, De Lange M, Harris JR, Hjelmberg JV, Luciano M, Martin NG, Mortensen J,**  
1006 **Nistico L, Pedersen NL, Skytthe A, Spector TD, Stazi MA, Willemsen G, and Kaprio J.**  
1007 Heritability of adult body height: a comparative study of twin cohorts in eight countries. *Twin*  
1008 *research : the official journal of the International Society for Twin Studies* 6: 399-408, 2003.

1009 122. **Sudol M.** Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds  
1010 to the SH3 domain of the Yes proto-oncogene product. *Oncogene* 9: 2145-2152, 1994.

1011 123. **Sudol M, Bork P, Einbond A, Kastury K, Druck T, Negrini M, Huebner K, and**  
1012 **Lehman D.** Characterization of the mammalian YAP (Yes-associated protein) gene and its

1013 role in defining a novel protein module, the WW domain. *JBiolChem* 270: 14733-14741,  
1014 1995.

1015 124. **Sudol M, and Harvey KF.** Modularity in the Hippo signaling pathway. *Trends*  
1016 *BiochemSci* 35: 627-633, 2010.

1017 125. **Taniguchi K, Wu LW, Grivennikov SI, de Jong PR, Lian I, Yu FX, Wang K, Ho**  
1018 **SB, Boland BS, Chang JT, Sandborn WJ, Hardiman G, Raz E, Maehara Y, Yoshimura**  
1019 **A, Zucman-Rossi J, Guan KL, and Karin M.** A gp130-Src-YAP module links inflammation  
1020 to epithelial regeneration. *Nature* 519: 57-62, 2015.

1021 126. **Taylor CT, and McElwain JC.** Ancient atmospheres and the evolution of oxygen  
1022 sensing via the hypoxia-inducible factor in metazoans. *Physiology* 25: 272-279, 2010.

1023 127. **Tipton KD, Borsheim E, Wolf SE, Sanford AP, and Wolfe RR.** Acute response of  
1024 net muscle protein balance reflects 24-h balance after exercise and amino acid ingestion.  
1025 *AmJPhysiol EndocrinolMetab* 284: E76-E89, 2003.

1026 128. **Tipton KD, Ferrando AA, Phillips SM, Doyle D, Jr., and Wolfe RR.** Postexercise  
1027 net protein synthesis in human muscle from orally administered amino acids. *AmJPhysiol*  
1028 276: E628-E634, 1999.

1029 129. **Tremblay AM, and Camargo FD.** Hippo signaling in mammalian stem cells.  
1030 *SeminCell DevBiol* 23: 818-826, 2012.

1031 130. **Tsika RW, Ma L, Kehat I, Schramm C, Simmer G, Morgan B, Fine DM, Hanft LM,**  
1032 **McDonald KS, Molkentin JD, Krenz M, Yang S, and Ji J.** TEAD-1 overexpression in the  
1033 mouse heart promotes an age-dependent heart dysfunction. *The Journal of biological*  
1034 *chemistry* 285: 13721-13735, 2010.

1035 131. **Tsika RW, McCarthy J, Karasseva N, Ou Y, and Tsika GL.** Divergence in species  
1036 and regulatory role of beta -myosin heavy chain proximal promoter muscle-CAT elements.  
1037 *American journal of physiology Cell physiology* 283: C1761-1775, 2002.

1038 132. **Tsika RW, Schramm C, Simmer G, Fitzsimons DP, Moss RL, and Ji J.**  
1039 Overexpression of TEAD-1 in Transgenic Mouse Striated Muscles Produces a Slower  
1040 Skeletal Muscle Contractile Phenotype. *JBiolChem* 283: 36154-36167, 2008.

1041 133. **Tumaneng K, Schlegelmilch K, Russell RC, Yimlamai D, Basnet H, Mahadevan**  
1042 **N, Fitamant J, Bardeesy N, Camargo FD, and Guan KL.** YAP mediates crosstalk between



1043 the Hippo and PI(3)K-TOR pathways by suppressing PTEN via miR-29. *NatCell Biol* 14:  
1044 1322-1329, 2012.

1045 134. **Udan RS, Kango-Singh M, Nolo R, Tao C, and Halder G.** Hippo promotes  
1046 proliferation arrest and apoptosis in the Salvador/Warts pathway. *NatCell Biol* 5: 914-920,  
1047 2003.

1048 135. **Ulbricht A, Eppler FJ, Tapia VE, Van d, V, Hampe N, Hersch N, Vakeel P, Stadel**  
1049 **D, Haas A, Saftig P, Behrends C, Furst DO, Volkmer R, Hoffmann B, Kolanus W, and**  
1050 **Hohfeld J.** Cellular mechanotransduction relies on tension-induced and chaperone-assisted  
1051 autophagy. *CurrBiol* 23: 430-435, 2013.

1052 136. **Ulbricht A, Gehlert S, Leciejewski B, Schiffer T, Bloch W, and Hohfeld J.**  
1053 Induction and adaptation of chaperone-assisted selective autophagy CASA in response to  
1054 resistance exercise in human skeletal muscle. *Autophagy* 11: 538-546, 2015.

1055 137. **Varelas X, Samavarchi-Tehrani P, Narimatsu M, Weiss A, Cockburn K, Larsen**  
1056 **BG, Rossant J, and Wrana JL.** The Crumbs complex couples cell density sensing to Hippo-  
1057 dependent control of the TGF-beta-SMAD pathway. *DevCell* 19: 831-844, 2010.

1058 138. **Vassilev A, Kaneko KJ, Shu H, Zhao Y, and DePamphilis ML.** TEAD/TEF  
1059 transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein  
1060 localized in the cytoplasm. *Genes Dev* 15: 1229-1241, 2001.

1061 139. **Von Gise A, Lin Z, Schlegelmilch K, Honor LB, Pan GM, Buck JN, Ma Q,**  
1062 **Ishiwata T, Zhou B, Camargo FD, and Pu WT.** YAP1, the nuclear target of Hippo signaling,  
1063 stimulates heart growth through cardiomyocyte proliferation but not hypertrophy.  
1064 *ProcNatlAcadSciUSA* 109: 2394-2399, 2012.

1065 140. **Vyas DR, McCarthy JJ, Tsika GL, and Tsika RW.** Multiprotein complex formation at  
1066 the beta myosin heavy chain distal muscle CAT element correlates with slow muscle  
1067 expression but not mechanical overload responsiveness. *The Journal of biological chemistry*  
1068 276: 1173-1184, 2001.

1069 141. **Wackerhage H, Del Re DP, Judson RN, Sudol M, and Sadoshima J.** The Hippo  
1070 signal transduction network in skeletal and cardiac muscle. *Science signaling* 7: re4, 2014.

1071 142. **Wagner PD.** A re-analysis of the 1968 Saltin et al. "Bedrest" paper. *Scand J Med Sci*  
1072 *Sports* 25 Suppl 4: 83-87, 2015.

- 1073 143. **Wang K, Degerny C, Xu M, and Yang XJ.** YAP, TAZ, and Yorkie: a conserved  
1074 family of signal-responsive transcriptional coregulators in animal development and human  
1075 disease. *BiochemCell Biol* 87: 77-91, 2009.
- 1076 144. **Wang P, Mao B, Luo W, Wei B, Jiang W, Liu D, Song L, Ji G, Yang Z, Lai YQ,**  
1077 **and Yuan Z.** The alteration of Hippo/YAP signaling in the development of hypertrophic  
1078 cardiomyopathy. *Basic Res Cardiol* 109: 435, 2014.
- 1079 145. **Wang W, Xiao ZD, Li X, Aziz KE, Gan B, Johnson RL, and Chen J.** AMPK  
1080 modulates Hippo pathway activity to regulate energy homeostasis. *Nature cell biology* 17:  
1081 490-499, 2015.
- 1082 146. **Waring CD, Vicinanza C, Papalamprou A, Smith AJ, Purushothaman S,**  
1083 **Goldspink DF, Nadal-Ginard B, Torella D, and Ellison GM.** The adult heart responds to  
1084 increased workload with physiologic hypertrophy, cardiac stem cell activation, and new  
1085 myocyte formation. *Eur Heart J* 35: 2722-2731, 2014.
- 1086 147. **Watt KI, Judson R, Medlow P, Reid K, Kurth TB, Burniston JG, Ratkevicius A,**  
1087 **De Bari C, and Wackerhage H.** Yap is a novel regulator of C2C12 myogenesis.  
1088 *BiochemBiophysResCommun* 393: 619-624, 2010.
- 1089 148. **Watt KI, Turner BJ, Hagg A, Zhang X, Davey JR, Qian H, Beyer C, Winbanks CE,**  
1090 **Harvey KF, and Gregorevic P.** The Hippo pathway effector YAP is a critical regulator of  
1091 skeletal muscle fibre size. *Nature communications* 6: 6048, 2015.
- 1092 149. **Wei B, Dui W, Liu D, Xing Y, Yuan Z, and Ji G.** MST1, a key player, in enhancing  
1093 fast skeletal muscle atrophy. *BMC Biol* 11: 12, 2013.
- 1094 150. **Wennmann DO, Vollenbroeker B, Eckart AK, Bonse J, Erdmann F, Wolters DA,**  
1095 **Schenk LK, Schulze U, Kremerskothen J, Weide T, and Pavenstadt H.** The Hippo  
1096 pathway is controlled by Angiotensin II signaling and its reactivation induces apoptosis in  
1097 podocytes. *Cell death & disease* 5: e1519, 2014.
- 1098 151. **Wilson JM, Loenneke JP, Jo E, Wilson GJ, Zourdos MC, and Kim JS.** The effects  
1099 of endurance, strength, and power training on muscle fiber type shifting. *Journal of strength*  
1100 *and conditioning research / National Strength & Conditioning Association* 26: 1724-1729,  
1101 2012.
- 1102 152. **Wood AR, Esko T, Yang J, Vedantam S, Pers TH, Gustafsson S, Chu AY,**  
1103 **Estrada K, Luan J, Kutalik Z, Amin N, Buchkovich ML, Croteau-Chonka DC, Day FR,**

1104 Duan Y, Fall T, Fehrmann R, Ferreira T, Jackson AU, Karjalainen J, Lo KS, Locke AE,  
 1105 Magi R, Mihailov E, Porcu E, Randall JC, Scherag A, Vinkhuyzen AA, Westra HJ,  
 1106 Winkler TW, Workalemahu T, Zhao JH, Absher D, Albrecht E, Anderson D, Baron J,  
 1107 Beekman M, Demirkan A, Ehret GB, Feenstra B, Feitosa MF, Fischer K, Fraser RM,  
 1108 Goel A, Gong J, Justice AE, Kanoni S, Kleber ME, Kristiansson K, Lim U, Lotay V, Lui  
 1109 JC, Mangino M, Mateo Leach I, Medina-Gomez C, Nalls MA, Nyholt DR, Palmer CD,  
 1110 Pasko D, Pechlivanis S, Prokopenko I, Ried JS, Ripke S, Shungin D, Stancakova A,  
 1111 Strawbridge RJ, Sung YJ, Tanaka T, Teumer A, Trompet S, van der Laan SW, van  
 1112 Setten J, Van Vliet-Ostaptchouk JV, Wang Z, Yengo L, Zhang W, Afzal U, Arnlov J,  
 1113 Arscott GM, Bandinelli S, Barrett A, Bellis C, Bennett AJ, Berne C, Bluher M, Bolton  
 1114 JL, Bottcher Y, Boyd HA, Bruinenberg M, Buckley BM, Buyske S, Caspersen IH,  
 1115 Chines PS, Clarke R, Claudi-Boehm S, Cooper M, Daw EW, De Jong PA, Deelen J,  
 1116 Delgado G, Denny JC, Dhonukshe-Rutten R, Dimitriou M, Doney AS, Dorr M, Eklund N,  
 1117 Eury E, Folkersen L, Garcia ME, Geller F, Giedraitis V, Go AS, Grallert H, Grammer TB,  
 1118 Grassler J, Gronberg H, de Groot LC, Groves CJ, Haessler J, Hall P, Haller T, Hallmans  
 1119 G, Hannemann A, Hartman CA, Hassinen M, Hayward C, Heard-Costa NL, Helmer Q,  
 1120 Hemani G, Henders AK, Hillege HL, Hlatky MA, Hoffmann W, Hoffmann P, Holmen O,  
 1121 Houwing-Duistermaat JJ, Illig T, Isaacs A, James AL, Jeff J, Johansen B, Johansson  
 1122 A, Jolley J, Juliusdottir T, Junttila J, Kho AN, Kinnunen L, Klopp N, Kocher T, Kratzer  
 1123 W, Lichtner P, Lind L, Lindstrom J, Lobbens S, Lorentzon M, Lu Y, Lyssenko V,  
 1124 Magnusson PK, Mahajan A, Maillard M, McArdle WL, McKenzie CA, McLachlan S,  
 1125 McLaren PJ, Menni C, Merger S, Milani L, Moayyeri A, Monda KL, Morken MA, Muller  
 1126 G, Muller-Nurasyid M, Musk AW, Narisu N, Nauck M, Nolte IM, Nothen MM, Oozageer  
 1127 L, Pilz S, Rayner NW, Renstrom F, Robertson NR, Rose LM, Roussel R, Sanna S,  
 1128 Scharnagl H, Scholtens S, Schumacher FR, Schunkert H, Scott RA, Sehmi J,  
 1129 Seufferlein T, Shi J, Silventoinen K, Smit JH, Smith AV, Smolonska J, Stanton AV,  
 1130 Stirrups K, Stott DJ, Stringham HM, Sundstrom J, Swertz MA, Syvanen AC, Tayo BO,  
 1131 Thorleifsson G, Tyrer JP, van Dijk S, van Schoor NM, van der Velde N, van Heemst D,  
 1132 van Oort FV, Vermeulen SH, Verweij N, Vonk JM, Waite LL, Waldenberger M,  
 1133 Wennauer R, Wilkens LR, Willenborg C, Wilsgaard T, Wojczynski MK, Wong A, Wright  
 1134 AF, Zhang Q, Arveiler D, Bakker SJ, Beilby J, Bergman RN, Bergmann S, Biffar R,  
 1135 Blangero J, Boomsma DI, Bornstein SR, Bovet P, Brambilla P, Brown MJ, Campbell H,  
 1136 Caulfield MJ, Chakravarti A, Collins R, Collins FS, Crawford DC, Cupples LA, Danesh  
 1137 J, de Faire U, den Ruijter HM, Erbel R, Erdmann J, Eriksson JG, Farrall M, Ferrannini  
 1138 E, Ferrieres J, Ford I, Forouhi NG, Forrester T, Gansevoort RT, Gejman PV, Gieger C,  
 1139 Golay A, Gottesman O, Gudnason V, Gyllenstein U, Haas DW, Hall AS, Harris TB,  
 1140 Hattersley AT, Heath AC, Hengstenberg C, Hicks AA, Hindorff LA, Hingorani AD,

1141 Hofman A, Hovingh GK, Humphries SE, Hunt SC, Hypponen E, Jacobs KB, Jarvelin  
 1142 MR, Jousilahti P, Jula AM, Kaprio J, Kastelein JJ, Kayser M, Kee F, Keinanen-  
 1143 Kiukaanniemi SM, Kiemeny LA, Kooner JS, Kooperberg C, Koskinen S, Kovacs P,  
 1144 Kraja AT, Kumari M, Kuusisto J, Lakka TA, Langenberg C, Le Marchand L, Lehtimäki  
 1145 T, Lupoli S, Madden PA, Mannisto S, Manunta P, Marette A, Matise TC, McKnight B,  
 1146 Meitinger T, Moll FL, Montgomery GW, Morris AD, Morris AP, Murray JC, Nelis M,  
 1147 Ohlsson C, Oldehinkel AJ, Ong KK, Ouwehand WH, Pasterkamp G, Peters A,  
 1148 Pramstaller PP, Price JF, Qi L, Raitakari OT, Rankinen T, Rao DC, Rice TK, Ritchie M,  
 1149 Rudan I, Salomaa V, Samani NJ, Saramies J, Sarzynski MA, Schwarz PE, Sebert S,  
 1150 Sever P, Shuldiner AR, Sinisalo J, Steinthorsdottir V, Stolk RP, Tardif JC, Tonjes A,  
 1151 Tremblay A, Tremoli E, Virtamo J, Vohl MC, Electronic Medical R, Genomics C,  
 1152 Consortium MI, Consortium P, LifeLines Cohort S, Amouyel P, Asselbergs FW,  
 1153 Assimes TL, Bochud M, Boehm BO, Boerwinkle E, Bottinger EP, Bouchard C, Cauchi  
 1154 S, Chambers JC, Chanock SJ, Cooper RS, de Bakker PI, Dedoussis G, Ferrucci L,  
 1155 Franks PW, Froguel P, Groop LC, Haiman CA, Hamsten A, Hayes MG, Hui J, Hunter  
 1156 DJ, Hveem K, Jukema JW, Kaplan RC, Kivimäki M, Kuh D, Laakso M, Liu Y, Martin NG,  
 1157 Marz W, Melbye M, Moebus S, Munroe PB, Njolstad I, Oostra BA, Palmer CN, Pedersen  
 1158 NL, Perola M, Perusse L, Peters U, Powell JE, Power C, Quertermous T, Rauramaa R,  
 1159 Reinmaa E, Ridker PM, Rivadeneira F, Rotter JI, Saaristo TE, Saleheen D,  
 1160 Schlessinger D, Slagboom PE, Snieder H, Spector TD, Strauch K, Stumvoll M,  
 1161 Tuomilehto J, Uusitupa M, van der Harst P, Volzke H, Walker M, Wareham NJ, Watkins  
 1162 H, Wichmann HE, Wilson JF, Zanen P, Deloukas P, Heid IM, Lindgren CM, Mohlke KL,  
 1163 Speliotes EK, Thorsteinsdottir U, Barroso I, Fox CS, North KE, Strachan DP,  
 1164 Beckmann JS, Berndt SI, Boehnke M, Borecki IB, McCarthy MI, Metspalu A,  
 1165 Stefansson K, Uitterlinden AG, van Duijn CM, Franke L, Willer CJ, Price AL, Lettre G,  
 1166 Loos RJ, Weedon MN, Ingelsson E, O'Connell JR, Abecasis GR, Chasman DI, Goddard  
 1167 ME, Visscher PM, Hirschhorn JN, and Frayling TM. Defining the role of common variation  
 1168 in the genomic and biological architecture of adult human height. *Nature genetics* 46: 1173-  
 1169 1186, 2014.

1170 153. Xiang L, Gilkes DM, Hu H, Luo W, Bullen JW, Liang H, and Semenza GL. HIF-  
 1171 1α and TAZ serve as reciprocal co-activators in human breast cancer cells. *Oncotarget*  
 1172 6: 11768-11778, 2015.

1173 154. Xin M, Kim Y, Sutherland LB, Murakami M, Qi X, McAnally J, Porrello ER,  
 1174 Mahmoud AI, Tan W, Shelton JM, Richardson JA, Sadek HA, Bassel-Duby R, and

1175 **Olson EN.** Hippo pathway effector Yap promotes cardiac regeneration.  
1176 *ProcNatlAcadSciUSA* 2013.

1177 155. **Xin M, Olson EN, and Bassel-Duby R.** Mending broken hearts: cardiac  
1178 development as a basis for adult heart regeneration and repair. *NatRevMolCell Biol* 14: 529-  
1179 541, 2013.

1180 156. **Xu T, Wang W, Zhang S, Stewart RA, and Yu W.** Identifying tumor suppressors in  
1181 genetic mosaics: the *Drosophila* lats gene encodes a putative protein kinase. *Development*  
1182 121: 1053-1063, 1995.

1183 157. **Yang Z, Nakagawa K, Sarkar A, Maruyama J, Iwasa H, Bao Y, Ishigami-Yuasa M,**  
1184 **Ito S, Kagechika H, Hata S, Nishina H, Abe S, Kitagawa M, and Hata Y.** Screening with a  
1185 Novel Cell-Based Assay for TAZ Activators Identifies a Compound That Enhances  
1186 Myogenesis in C2C12 Cells and Facilitates Muscle Repair in a Muscle Injury Model.  
1187 *Molecular and cellular biology* 34: 1607-1621, 2014.

1188 158. **Yu FX, Zhang Y, Park HW, Jewell JL, Chen Q, Deng Y, Pan D, Taylor SS, Lai ZC,**  
1189 **and Guan KL.** Protein kinase A activates the Hippo pathway to modulate cell proliferation  
1190 and differentiation. *Genes Dev* 27: 1223-1232, 2013.

1191 159. **Yu FX, Zhao B, and Guan KL.** Hippo Pathway in Organ Size Control, Tissue  
1192 Homeostasis, and Cancer. *Cell* 163: 811-828, 2015.

1193 160. **Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH, Zhao J, Yuan H,**  
1194 **Tumaneng K, Li H, Fu XD, Mills GB, and Guan KL.** Regulation of the Hippo-YAP Pathway  
1195 by G-Protein-Coupled Receptor Signaling. *Cell* 150: 780-791, 2012.

1196 161. **Yuan Z, Kim D, Shu S, Wu J, Guo J, Xiao L, Kaneko S, Coppola D, and Cheng**  
1197 **JQ.** Phosphoinositide 3-kinase/Akt inhibits MST1-mediated pro-apoptotic signaling through  
1198 phosphorylation of threonine 120. *JBiolChem* 285: 3815-3824, 2010.

1199 162. **Zhao B, Li L, Tumaneng K, Wang CY, and Guan KL.** A coordinated  
1200 phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). *Genes*  
1201 *Dev* 24: 72-85, 2010.

1202 163. **Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L,**  
1203 **Zheng P, Ye K, Chinnaiyan A, Halder G, Lai ZC, and Guan KL.** Inactivation of YAP  
1204 oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth  
1205 control. *Genes Dev* 21: 2747-2761, 2007.

1206 164. **Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu J, Lin JD, Wang CY, Chinnaiyan AM, Lai**  
1207 **ZC, and Guan KL.** TEAD mediates YAP-dependent gene induction and growth control.  
1208 *Genes Dev* 22: 1962-1971, 2008.

1209 165. **Zheng Y, Wang W, Liu B, Deng H, Uster E, and Pan D.** Identification of  
1210 Happyhour/MAP4K as Alternative Hpo/Mst-like Kinases in the Hippo Kinase Cascade.  
1211 *Developmental cell* 34: 642-655, 2015.

1212 166. **Zhu X, Topouzis S, Liang LF, and Stotish RL.** Myostatin signaling through Smad2,  
1213 Smad3 and Smad4 is regulated by the inhibitory Smad7 by a negative feedback mechanism.  
1214 *Cytokine* 26: 262-272, 2004.

1215

1216

